Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

  Exhibit 4.1    
    

          

  

SQI DIAGNOSTICS INC.  

 ANNUAL INFORMATION FORM  

 June 15, 2011  

 

 TABLE OF CONTENTS  

 

 

			
	 
	 	Page 
	 FORWARD-LOOKING STATEMENTS
	 	3
	 CORPORATE STRUCTURE
	 	5
	 GENERAL DEVELOPMENT OF THE BUSINESS
	 	5
	 DESCRIPTION OF THE BUSINESS
	 	7
	 RISK FACTORS
	 	23
	 DIVIDENDS AND DISTRIBUTIONS
	 	36
	 DESCRIPTION OF CAPITAL STRUCTURE
	 	36
	 MARKET FOR SECURITIES
	 	37
	 DIRECTORS AND OFFICERS
	 	39
	 LEGAL PROCEEDINGS AND REGULATORY ACTIONS
	 	43
	 TRANSFER AGENTS AND REGISTRARS
	 	43
	 EXPERTS
	 	43
	 ADDITIONAL INFORMATION
	 	43

 

 2

 

 SQI DIAGNOSTICS INC.

ANNUAL INFORMATION FORM  

        In this annual information form ("Annual Information Form"), unless otherwise
indicated, all dollar amounts are expressed in Canadian dollars and the statistical and financial data are presented as of June 15, 2011. 

 
 

  FORWARD-LOOKING STATEMENTS    
    

        This Annual Information Form, including the documents incorporated by reference into this Annual Information Form, contains
forward-looking statements. These statements relate to future events or future performance and reflect our expectations and assumptions regarding our growth, results of operations, performance and
business prospects and opportunities. Such forward-looking statements reflect our current beliefs and are based on information currently available to us. In some cases, forward-looking statements can
be identified by terminology such as "our goal", "may", "would", "could", "will", "should", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential", "continue" or the
negative of these terms or other similar expressions concerning matters that are not historical facts. The forward-looking statements in this Annual Information Form, including any documents
incorporated by reference into this Annual Information Form, include, among others, statements regarding
our future operating results, economic performance and product development efforts, and statements in respect of: 

	•
	our expected future losses and accumulated deficit levels;  

	•
	our requirement for, and our ability to obtain, future funding on favourable terms or
at all;

	•
	market competition and technological advances of competitive products;  

	•
	our expectations regarding the acceptance of our products by the
market;  

	•
	our expectations regarding the progress and the successful and timely completion of the various
stages of the regulatory clearance process;

	•
	our strategy to develop new products and to enhance the capabilities of existing
products;

	•
	our strategy with respect to research and development;  

	•
	our dependence on expanding our customer base;  

	•
	our plans to market, sell and distribute our products;  

	•
	our plans in respect of strategic partnerships for research and
development;  

	•
	our ability to obtain a sufficient supply of the components needed for
our systems;

	•
	our plans to retain and recruit personnel;  

	•
	our ability to satisfy customer demand for our systems;  

	•
	our plans to correct defects or errors in our systems;  

	•
	the effect of litigation on our business;  

	•
	our strategy with respect to the protection of our intellectual property;
and  

	•
	our expectations with respect to existing and future corporate alliances and licensing
transactions with third parties, and the receipt and timing of any payments to be made by us or to us in respect of such arrangements.

        A
number of factors could cause actual events, performance or results, including those in respect of the foregoing items, to differ materially from the events, performance and results
discussed in the forward-looking 

3

 

statements.
Factors that could cause actual events, performance or results to differ materially from those set forth in the forward-looking statements include, but are not
limited to: 

	•
	the extent of our future losses;  

	•
	our ability to obtain the capital required to fund development and
operations;

	•
	development or commercialization of similar products by our competitors;  

	•
	our ability to develop and market our products;   

	•
	our ability to comply with applicable governmental and securities regulations
and standards;

	•
	our ability to develop and commercialize our technologies;   

	•
	delays or failures in our ability to develop and implement new diagnostic
products;

	•
	our reliance on a few key and significant customers;  

	•
	the impact of changes in the business strategies and development priorities of our strategic
partners;

	•
	loss of suppliers or increases to the cost of the components of our
systems;  

	•
	the impact of legislative changes to the healthcare system and regulatory
process;

	•
	our ability to attract and retain skilled and experienced personnel;  

	•
	damage to our manufacturing facility or its failure to accommodate future
sales growth;

	•
	the impact of unknown defects or errors and product liability claims;  

	•
	the impact of liability from the use of hazardous and biological materials and
other claims;

	•
	our ability to successfully manage fluctuations in revenue;   

	•
	foreign currency fluctuations;  

	•
	our ability to obtain patent protection and protect our intellectual property rights and not
infringe on the intellectual property rights of others;

	•
	the expense and potential harm to our business of intellectual property
litigation;

	•
	stock market volatility;  

	•
	changing market conditions;  

	•
	the fact that further equity financing may substantially dilute the interests of our
shareholders; and  

	•
	other risks detailed from time-to-time in our ongoing quarterly filings,
annual information forms, annual reports and annual filings with applicable securities regulators, and those which are discussed under the heading "Risk Factors".

        Although
the forward-looking statements contained in this Annual Information Form and in the documents incorporated by reference are based on what we consider to be reasonable
assumptions based on information currently available to us, there can be no assurance that actual events, performance or results will be consistent with these forward-looking statements, and our
assumptions may prove to be incorrect. These forward-looking statements are made as of the date of this Annual Information Form. 

        Forward-looking
statements made in a document incorporated by reference into this Annual Information Form are made as of the date of the original document and have not been updated by us
except as expressly provided for in this Annual Information Form. Except as required under applicable securities legislation, we undertake no obligation to publicly update or revise forward-looking
statements, whether as a result of new information, future events or otherwise. 

4

 

 
 

  CORPORATE STRUCTURE    
    

        The principal and registered office of SQI Diagnostics Inc. ("SQI" or the
"Company" and, in this Annual Information Form, "we", "us" and "our" refer to the Company unless the context otherwise requires) is located at
36 Meteor Drive, Toronto, ON M9W 1A4. SQI has a single subsidiary, SQI Diagnostics Systems Inc. ("SQIDS"), which is wholly-owned. 

        Emblem
Capital Inc., the predecessor to SQI, was incorporated on September 11, 2003 pursuant to the Canada Business Corporation
Act (the "CBCA") and filed articles of amendment to change its name to "SQI Diagnostics Inc." 

        On
April 20, 2007, an amalgamation between Umedik Inc. and 670194 Canada Inc., a wholly-owned subsidiary of Emblem Capital Inc., was completed and the
amalgamated company changed its name to "SQI Diagnostics Systems Inc." on September 7, 2007. 

        The
predecessor to Umedik Inc. was formed on April 19, 1999 pursuant to the Business Corporations Act (Ontario) under the
corporate name of Pockit Corporation. Pockit Corporation filed articles of amendment on June 9, 1999 to change its name to Poc    •    Kit Corporation.
Poc    •    Kit Corporation was continued under the CBCA on December 1, 1999 under the name of e-umedik Inc. and
e-umedik Inc. filed articles of amendment on October 20,
2000 to change its name to Umedik Inc. 6701914 Canada Inc. was incorporated on January 12, 2007 pursuant to the CBCA. 

 
 

  GENERAL DEVELOPMENT OF THE BUSINESS    
    

        Our business was founded in 1999 on the concept that more sensitive, timely and less costly disease diagnostics based on antigen,
protein and antibody detection would benefit healthcare providers. We believed that diagnostic testing based on enzyme-linked immunosorbent assay
("ELISA") technology, a test involving an enzyme and an antibody, the diagnostic technology used at the time, had not changed significantly since its
development in the 1950s and lacked accuracy and sensitivity, while the testing procedures were lengthy, difficult to execute and labour intensive. We also believed that DNA microarray technology,
which was instrumental throughout the 1990s in mapping the human genome, could provide the basis for new antigen, protein and antibody detection technology that could advance beyond the limitations
imposed by ELISA technology. However, antigen, protein and antibody microarrays present a very different set of challenges from the DNA microarrays used for the human genome project. 

        Until
1999, there was little published research on the use of microarrays for antigen, protein and antibody detection for human  in-vitro diagnostics ("IVD")
applications. Our founders believed the problem stemmed from
the following scientific problems: 

	•
	Microarray surface coatings and printing technology were not sufficiently advanced to enable antigen, protein and antibody
microarrays to be reliably printed with diagnostic grade signal;   

	•
	Users could not reliably or consistently measure multiple biomarkers (specifically, antigens, proteins and antibodies) in
the same test because these biomarkers have very different surface charge and binding characteristics; and   

	•
	High levels of variability were likely related to the lack of standardization and control of titer plate-based ELISA tests
leading to inaccurate or less predictable outcomes. 

        We
believe that we have addressed these problems with our platform that allows us to detect and measure multiple antibodies and their different sub-types in the same
two-dimensional planar microarray. Our use of specialty surface treatments and surface-coating processes allows us to create microarrays with consistent spot characteristics and limited
background noise (in other words, with high signal to noise ratios). Our two dimensional planar array design securely fixes all reagents used in an assay to the glass surface independently of
one another, which eliminates unwanted biochemical interactions. Our IgX PLEX technology can detect different antibody isotypes (IgA, IgG, IgM)
simultaneously from a single microarray spot using multiple detection wavelengths of light. Our calibration technology adjusts each microarray for every test, which reduces the variability that may
result from environmental factors or from the use of external calibrators. We have enhanced the precision of our microarrays through the use of our system, which uses a statistically valid number of 

5

 

replicate
spots for each biomarker being tested in combination with complex software algorithms. We believe that our technology delivers consistent, repeatable, precise test results and can measure
the concentration of multiple biomarkers in a single test. Our automated technology can analyze multiple patient samples simultaneously using less time, effort, and consumables than existing titer
plate technology. 

 Three Year History  

        The list below describes the development of the Company's business over the last three completed financial years. 

 

 

			
	 The Company completed a private placement of 2,439,500 shares at a price of $1.50 per share for cash proceeds of $3,349,700 and also issued broker
warrants for 194,200 common shares.
	 	June 2008
	 The Company received its license from Health Canada for the SQiDworks Diagnostics Platform. See "— Government
Regulation".
	 	

November 2008
	 The Company received its license from Health Canada for the QuantiSpot Rheumatoid Arthritis Assay. See "— Government
Regulation".
	 	

November 2008
	 The Company completed the first tranche of a non-brokered private placement of 2,400,000 common shares at a price of $1.25 per share
for gross proceeds of $3,000,000.
	 	

December 2008
	 The Company completed the second tranche of a non-brokered private placement of 1,331,500 common shares at a price of $1.25 per
share for gross proceeds of $1,664,375 and also issued 106,520 warrants.
	 	

January 2009
	 The Company's IgX PLEX Quantitative Assay and SQiDworks Diagnostics Platform were European Conformity ("CE") marked and registered. See "— Government Regulation".
	 	

February 2009
	 The Company's 510(k) submission for IgX PLEX Rheumatoid Arthritis Qualitative Assay and SQiDworks Diagnostics Platform was cleared by the
U.S. Food and Drug Administration ("FDA"). See "— Government Regulation".
	 	

October 2009
	 The Company completed a private placement of 2,398,104 units at a price of $2.75 per unit for gross proceeds of $6,594,786. Each
unit was comprised of one common share and one half common share purchase warrant. See "Market for Securities".
	 	

December 2009
	 The Company completed a private placement of 2,280,000 units at a price of $2.50 per unit for gross proceeds of $5,700,000. Each
unit was comprised of one common share and one half common share purchase warrant. See "Market for Securities".
	 	

August 2010
	 The Company received its license from Health Canada for the IgX PLEX Celiac Qualitative Assay. See "— Government
Regulation".
	 	

September 2010
	 The Company received its license from Health Canada for the IgX PLEX Celiac Panel. See "— Government Regulation".
	 	

April 2011
	 The Company received confirmation that its IgX PLEX Celiac quantitative assay had been CE marked and registered. See
"— Government Regulation".
	 	

June 2011
	 The Company's 510(k) submission for IgX PLEX Celiac Qualitative Assay and SQiDworks Diagnostics Platform was cleared by the FDA. See
"— Government Regulation".
	 	

June 2011

 

 6

 
 
 

  DESCRIPTION OF THE BUSINESS    
    

 General  

        We are a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray
diagnostics. Our goal is to become a leader in the development and commercialization of microarray and multiplexed diagnostics by offering our customers a comprehensive "turnkey" solution that
increases the efficiency and ease of diagnostic testing and test development. 

        Our
target customers — clinical, academic and diagnostic development laboratories — require diagnostic
processing equipment and consumable tests ("systems") that are capable of processing large numbers of patient samples at low cost and with minimal labour requirements ("high-throughput
systems"). High-throughput systems have not been widely employed in autoimmune disease, allergen or companion diagnostics testing and only limited use of high-throughput
systems exists in infectious disease testing. To our knowledge, no fully-automated high-throughput systems exist that are capable of addressing the combined multiplex testing needs of
these markets. A fully-automated system capable of providing multiple biomarker measurements in a single test array has the potential to increase a laboratory's throughput with significantly less
labour, consumables and other costs. 

        Our
proprietary microarray tests and fully-automated instruments are designed to simplify antigen, protein and antibody testing workflow, increase throughput and reduce costs, all while
providing excellent data quality. In many instances, our technology enables analysis that was traditionally unavailable. 

        Our
principal lines of business include: 

	•
	the development, manufacturing, and marketing of fully-automated diagnostic instruments (our "platform");  

	•
	the development and marketing of tests for the autoimmune, allergen, infectious disease and companion diagnostics testing
markets (our "assays"); and   

	•
	the commercialization of microarray printing technology (our "printing solutions"). 

 Our Platform  

        Our FDA-cleared SQiDworks platform is comprised of three key elements: a proprietary one-time-use
consumable microarray device, a validated and integrated instrument system that fully-automates the processing of patient samples in the microarray device, and a proprietary software processing system
that processes and analyses the array and reports the presence or absence of a biomarker ("qualitative testing") and/or the amount of biomarker present ("quantitative testing"). Our SQiDworks platform
can perform qualitative or quantitative testing for multiple biomarkers simultaneously. Our SQiDworks platform is currently the only FDA-cleared, fully-automated, microarray system and
multiplexing solution in our target markets and we believe there are significant barriers to entry in these markets. We believe that our SQiDworks platform addresses many of the key challenges faced
by our customers today by delivering accurate patient results in less time and with significantly reduced labour, consumables and other costs. 

        We
are developing SQiDlite, our fully-automated, bench-top diagnostic platform for both IVD and research use only ("RUO")
applications. We are also currently commercializing SQiDman, our small semi-automated platform for processing microarrays, to be used by research customers or development partners for RUO
applications in the microarray development process. 

 Our Assays and the Development of Our Test Menu  

        We have received regulatory clearance to market our qualitative rheumatoid arthritis and celiac assays in the United States, our
qualitative and quantitative rheumatoid arthritis and celiac assays in Canada, and our quantitative rheumatoid arthritis and celiac assays in the European Union for use on our SQiDworks platform. We
have a robust pipeline of autoimmune tests and one companion diagnostic test in development, and plan to develop a broad test menu for autoimmune disease, companion diagnostics, infectious disease and
allergen testing markets in the future. Our current in-development tests include multiplexed panels to aid in the diagnosis 

7

 

of
vasculitis, lupus, Crohn's disease and inflammatory bowel disease ("IBD") and in the management of treatment of autoimmune affected patients with a
class of drugs referred to as "anti-TNF drugs" such as Remicade®, Enbrel® and
Humira®. We are currently developing more sensitive rheumatoid arthritis and celiac assays that measure additional biomarkers. 

        We
have targeted these testing markets because we believe: 

	•
	healthcare providers require the measurement of multiple biomarkers to aid in the diagnosis and therapeutic monitoring of
these diseases;   

	•
	these testing markets are underserved by fully-automated, high-throughput, multiplexed systems;  

	•
	tests in these markets are generally run at sufficiently high volumes in larger test facilities that would benefit from
both multiplexing and automation; and   

	•
	these tests typically qualify for private and public reimbursement in Canada, the United States, and the
European Union. 

        One
of our key operational goals is to continue to develop and seek regulatory approval for additional tests, as we believe that expanding our "test menu" will drive adoption of our
platform and products by customers. 

        The
development of our test menu is augmented by our partnerships with leading research institutions, including Beth Israel Deaconess Medical Center, the Cleveland Clinic, and the
University of North Carolina. Our partnerships provide us with many advantages, including the rights to approximately 10,800 patient samples, which aid us in the development and validation of
our assays. 

        We
also offer development services and manufacturing of diagnostic kits and microarrays to our customers. We will convert content of laboratories and third parties into microarray
products, manufacture microarray test kits for sale to these customers and, in the case of third parties, enable them to re-sell our high throughput systems on which these proprietary
assays can be run. Our laboratory customers may use these custom microarray components to perform diagnostic test services using our platforms and may subsequently sell the results to their customers. 

 The Market for Our Products  

        The diagnostic products and services market is increasing in importance, complexity, breadth and size. Diagnostics are critical to
high-quality healthcare and guide a majority of clinical decisions. 

        Over
the last forty years, the number of biomarkers that can be measured by commercial laboratories has grown dramatically, with less than 4,000 different types of biomarker
measured in the 1970s, more than doubling to approximately 10,000 with automation in the 1980s, and increasing to approximately 25,000 in the early 2000s. 

        Since
1976, the number of biomarkers measured by assays cleared through the FDA's 510(K) process to aid in the diagnosis of the six autoimmune diseases that comprise our target market
has increased from four to 48. This represents an increase in the average number of biomarkers per disease state in our autoimmune disease target market from 0.7 to 8. We believe that this increase in
biomarkers is indicative of a healthcare trend whereby healthcare providers are seeking to run diagnostic tests for increasing numbers of biomarkers to assist in the diagnosis of disease. 

        Researchers
and laboratories are accelerating the rate at which new biomarkers are being commercialized for the known set of diseases being diagnosed today. It is estimated that an
additional 30,000 biomarkers (molecular and protein) in various stages of development have been identified and not yet commercialized. We believe that the increased use of existing assays and
the introduction of new assays will drive growth of the diagnostics testing market, a market that is estimated to have a growth rate of approximately five to nine percent annually from 2009
to 2014. 

        Our
strategy is to focus initially on the immunoassay segment of the diagnostic test market since there are no multiplexed, microarray, IVD solutions in the immunoassay space. The 2012
global immunoassay diagnostic test market is estimated to be US$10.3 billion, of which approximately US$4.5 billion is within our strategic 

8

 

market
focus, which includes tests for autoimmune disease, infectious disease, and allergen tests. These three markets are estimated to be US$1.5 billion, US$2.4 billion and
US$0.6 billion, respectively. 

Autoimmune Disease Tests 

        Our
primary testing market in the immunoassay segment is for products that aid in the diagnosis of autoimmune disease, which is estimated to be approximately
US$1.5 billion per year. We have targeted the autoimmune testing segment for the following reasons: 

	•
	there are ten autoimmune disease states, which include the autoimmune diseases in our target market, that command most of
the blood testing revenues for the entire autoimmune testing segment;   

	•
	the most common tests for autoimmune diseases currently evaluate approximately 70 biomarkers, representing an
average of approximately seven biomarkers per disease;   

	•
	these tests are generally run at high volumes at larger test facilities and in batches and are not typically run on a "one
off" basis;   

	•
	generally, autoimmune disease tests have an established reimbursement model from private and public healthcare payers;  

	•
	each of the autoimmune diagnostic tests we are developing has "predicate" technologies with FDA clearance on older, single
biomarker, manual titer plate technology that we intend to replace;   

	•
	regulatory clearance for the majority of autoimmune assays is through the FDA 510(k) process, which is well
established; and   

	•
	autoimmune disease tests are regulated as Class II devices by the FDA. Class II diagnostic clearance is
generally obtained following a shorter review period than for a Class III device. See "— Government Regulation". 

Infectious Disease and Allergen Tests 

        We
also plan to enter the immunoassay segment of the infectious disease diagnostics market, which is estimated to be approximately US$2.4 billion for
2012, followed by the immunoassay segment of the allergen diagnostics market, which is approximately US$0.6 billion for 2012. 

Print Services 

        According
to a press release issued by F. Hoffmann-La Roche Ltd., in 2007 the estimated market for protein and molecular microarray print
equipment and services was approximately US$600 million per year. 

RUO and Lab -Developed Tests 

        Approximately
34% of the US$3.7 billion U.S. annual market for RUO and lab-developed tests is directly addressable by our proprietary
technologies. Additionally, we believe that the US$2.2 billion European market for RUO and lab-developed tests has approximately the same segmentation as the U.S. market. As
such, we anticipate that the combined U.S. and European markets for RUO and lab-developed tests that are directly addressable by our proprietary technologies to be approximately
US$2 billion. 

Companion Diagnostics 

        We
believe that the commercialization of "companion diagnostics" tests is a meaningful market opportunity for us. Autoimmune diseases are increasingly being
treated with antibody-based or other biologic drugs. Often, there are different variants of the antibody or biologic drugs. For example, anti-TNF-based drugs are used to treat
rheumatoid arthritis, Crohn's disease and IBD. The market for anti-TNF drugs was estimated to be approximately US$16 billion per year in 2008. Anti-TNF drugs are
currently marketed under brand names such as Remicade®, Enbrel® and
Humira®, which represented more than 99% of the anti-TNF drug market in 2008. The effectiveness of the treatment of autoimmune patients with
these drugs may be enhanced by the monitoring of the concentration of these drugs in a patient's blood by a "companion diagnostic" test. Our multiplexing 

9

 

technology
allows us to combine the tests for both the diagnosis and therapeutic monitoring of a patient's disease. We expect this test combination to result in significantly less labour, consumables
and other costs and provide us with a large market opportunity. 

 Diagnostics  

        Assays are used world-wide to assist healthcare providers in preventing, diagnosing and treating diseases. In order to be
able to determine whether someone has a particular disease, a typical assay will test for "biomarkers", a term used to refer to a specific antigen, protein or antibody. The amount or "concentration"
of the biomarker in a person's blood usually indicates one or more of the following: the predisposition or risk of getting the disease; presence or absence of the disease; and severity of the disease.
For example, assays have been used for more than 50 years to detect the presence of rheumatoid factors, which are diagnostic markers for rheumatoid arthritis. The use of assays to detect
rheumatoid factors first received 510(k) clearance by the FDA approximately 35 years ago. Rheumatoid factors can be detected in the blood of a patient before the first symptoms appear, can
indicate the progression of the disease, and provide information that may guide a healthcare provider's determination of a patient's treatment plan. 

        Diagnostics
"platforms" refer to the specific technology or instrument system on which a consumable device is "run" to generate test results. There are a number of different platforms on
which assays can be run. For example, ELISA plates and readers, ELISA bead technology and polymerase chain reaction are all platforms for running assays. 

        A
microarray is a device that is used to perform multiple tests simultaneously. A microarray is comprised of two principal elements.  

	•
	A surface upon which capture molecules are printed in the form of spots.
The surface is typically glass or plastic and is chemically coated to more easily "accept" and bind the molecules being printed without damaging the molecules.   

	•
	A physical superstructure to separate individual wells. Each well contains
numerous spots. Each of the spots within an individual well is analogous to a traditional microtiter plate test well. 

        The
biological and chemical reactions that occur in each test well generate multiple test results. Each of these test results is a billable event for our customers. 

 Limitations of Current Technologies  

        Clinical, academic, and diagnostic development laboratories are faced with increasing numbers of tests or experiments required to
support a diagnostic conclusion or development decision. In the diagnostic setting, there are a growing number of biomarkers that are used for each patient to aid in the diagnosis and monitoring of
many diseases. This has led to a growing workload of increasingly complex and costly diagnostic tests for laboratories. Additionally, laboratories face pressure to reduce overall healthcare
system costs. 

        Our
target customers — clinical, academic and diagnostic development laboratories — require diagnostic
processing equipment and consumable tests that are capable of processing large numbers of patient samples at low cost and with minimal labour requirements. High-throughput systems have not
been widely employed in autoimmune disease or allergen testing and limited use of high-throughput systems exists in infectious disease testing. To our knowledge, no
high-throughput systems exist that are capable of addressing the combined multiplex testing needs of these markets. A fully-automated system capable of providing multiple biomarker
measurements in a single test array has the potential to increase a laboratory's throughput with significantly less labour, consumables, and other costs. We believe these cost savings would be
realized because, among other things: 

	•
	a fully-automated system reduces "hands-on" technician time;   

	•
	the volume of liquid reagent is less and the number of other consumables, such as pipette tips, required to process one
microarray is fewer when compared to traditional methods of running multiple tests in multiple titer plates; 

10

 

	•
	the amount of serum required per patient to produce results on a 12 biomarker test is approximately
240 times greater using titer plates than using microarray plates;   

	•
	a laboratory does not incur the expense of sending some tests of a larger multiplex panel to other labs;  

	•
	the cost of management of multiple samples being tested by multiple technicians and combining the results to a single
report would be largely eliminated by multiplexing capability; and   

	•
	reducing the number of hands-on steps through automation would potentially reduce error rates. 

 Microtiter Plates  

        Laboratories almost exclusively use microtiter plates to perform immunoassay tests. The use of microtiter plates restricts an
immunoassay test to the analysis of a single biomarker. Microtiter plates are predominantly processed with a high contribution of direct labour. This increases the time to produce a test result and
the potential for error. Since equipment available to reduce labour is limited, the use of microtiter plates restricts the throughput of a laboratory. We estimate that 60% of our target customers'
costs to produce a diagnostic result are due to direct labour. 

        Skilled
laboratory labour capable of performing diagnostic testing in our target markets is limited and is expected to contribute to laboratories' growing cost structure at an increasing
rate. The United States Department of Health and Human Services reported in 2009 that by 2012, 138,000 lab professionals, including medical technicians and laboratory assistants, will be
needed, but fewer than 50,000 will be trained. 

 Multiplex Diagnostic Tests  

        A solution to the cost and labour constraints of immunoassay testing for single biomarkers is to perform diagnostic tests for multiple
biomarkers simultaneously in a single assay (a "multiplex diagnostic test"). The processes used to complete a single test within a diagnostic panel of several biomarkers are complex and
technically difficult. Such complexity has limited the throughput and efficiency of multiplex diagnostic testing, and technical challenges have restricted the widespread adoption of automated systems.
Most laboratories do not use automated processing equipment to augment their workforce in our key target markets where the measurement of multiple antigens, proteins or antibodies is required. 

 Bead-Based Array Systems  

        Bead-based array systems were initially developed for DNA-based testing and were subsequently adapted for
protein-based and antibody-based testing. Bead-based methods, however, have faced limitations that reduce their utility, particularly for multiplex diagnostics and experimentation. In
particular, the workflow for bead arrays is complex, time consuming and costly. For example, standard protocols for a nine-biomarker bead array require multiple complex operations
including approximately 190 steps and approximately five hours of "hands-on" time to complete. 

 Automated Systems  

        While laboratories use automated systems for many types of blood tests, to our knowledge, there are no fully-automated
high-throughput microarray systems. A number of diagnostics companies have developed automated single-plex fully-automated, bench-top systems for autoimmune testing
and we are only aware of one bead-based automated multiplex system. 

11

 

 Antigen, Protein and Antibody Microarrays and Their Technical Challenges  

        An alternate to bead-based array systems is a microarray printed on a two dimensional substrate. These antigen, protein and
antibody microarrays solve several limitations of bead-based systems such as interactions between beads, but are challenging to develop as we believe there are several technological
obstacles, including: 

	•
	precision and accuracy of printing;   

	•
	cross interference of similar molecules in the system;   

	•
	calibration and standardization of multiple separate molecular signals in a single microarray well; and  

	•
	complex software systems required to measure and analyze the multiple signals measured within the microarray. 

 Precision and Accuracy of Printing  

        Microarray printing has been traditionally done with contact printers that, like a quill pen, physically "spot" the biomarker capture
molecules onto the microarray surface. These contact methods of printing are imprecise and lead to microarrays with high degrees of variability and significant background noise. This reduces the
commercial applications of contact spotted microarrays. Contact spotting does not typically lead to IVD capable microarrays in antigen, protein and antibody applications. Some earlier versions of
non-contact printers are also used today, but these technologies have similar drawbacks to contact spot printers. 

 Cross Interference  

        The ability to discriminate among different "isotypes" (types) of individual target antibodies and different antigens and proteins is
important to the measurement of biomarkers and it has proven challenging to develop multiplex tests that discriminate between these different entities in a single microarray. 

 Calibration and Standardization  

        The processing of multiplex arrays is complex and is prone to high degrees of variation between test arrays. This error potentially
leads to reduced test performance and has restricted the use of multiplex arrays almost exclusively to the research market where there is a tolerance for less accurate measurements. 

        Diagnostic
approaches for measuring multiple antigen, protein or antibody biomarkers for large numbers of patients are generally unavailable or are not cleared or approved as IVD tests.
Multiplexing, as it is available today, does not adequately address antigen, protein and antibody focused measurement. Most multiplexing technologies have been developed and commercialized for the
processing of high-density genetic or molecular arrays. These technologies generally work from a different set of technological principles than those needed to measure multiple antigens,
proteins or antibodies. Further, these
technologies are used in a research setting and are generally inadequate for use in commercial diagnostic testing. 

 Software Systems  

        The sophistication of the automated systems and processing software required to analyze microarrays has restricted the commercial
viability of microarrays in diagnostic laboratories. 

 Our Solution  

        Our proprietary microarray tests and automated instruments are designed to simplify antigen, protein and antibody testing workflow,
increase throughput, reduce costs and provide excellent data quality. In many instances, our technology enables analysis that was traditionally unavailable. 

        Traditional
biomarker testing methods using microtiter plates require approximately four minutes on average of technician "hands-on" time per biomarker per patient ("test
effort"). For example, a four biomarker test for celiac on samples from 74 patients would, on average, require eight microtiter plates, assuming each patient's blood sample is tested in
duplicate using standard good laboratory practices. This would have traditionally required approximately 20 hours of direct "hands-on" labour using predicate technology. 

12

 

 Our Fully-Automated SQiDworks Diagnostic Platform  

        Our high-throughput SQiDworks diagnostic platform is a fully-automated microarray processing and analytical system capable
of 888 results per hour. By way of example, for a celiac assay that measures four biomarkers, our SQiDworks platform requires approximately 30 seconds of technician
"hands-on" time per patient per panel compared to approximately 16 minutes of technician "hands-on" time using microtiter plate technology, and uses one microarray kit
instead of 8 single biomarker microtiter kits to generate diagnostic results for the four biomarkers. The difference between the approximately 20 hours of direct hands-on
labour using microtiter plate
technology and the approximately 30 minutes of direct hands-on labour using our system results in significant cost savings, as does using one microarray kit rather than eight
microtiter kits. 

        Additionally,
the cost savings demonstrated above increase as the number of biomarkers per diagnostic test increase. For example, for a lupus test that measures twelve biomarkers, our
SQiDworks platform requires the same amount of technician "hands-on" time as the celiac assay, and also requires only one microarray kit. However, microtiter plate technology would require
approximately 48 minutes of technician "hands-on" time per patient per panel and the use of 24 single biomarker microtiter kits. This equates to a reduction of approximately
59 hours of direct hands-on labour using our system as well as greater savings with respect to consumables. 

 Our IgX  PLEX Microarrays  

        Our IgX  PLEX  microarrays have the ability to discriminate between individual isotypes of antibodies and antigens and proteins within a single
well of a
microarray, resulting in the measurement of multiple biomarkers in a single test. 

        Our
microarray technology requires the use of significantly less patient blood than traditional methods. Our system requires a ten microliter drop of blood to be processed from a single
sample tube, compared to the multiple milliliters of blood used by traditional methods. Our system dispenses the single drop of blood once per patient in a microarray well. Traditional methods require
multiple blood samples to be manipulated into multiple test vessels over many steps. The reduction in processing steps and the ability to generate simultaneous multiplexed measurements from a single
drop of blood increase the predictive value of the test. The increased predictive value of the test would allow the healthcare provider to choose a treatment plan earlier in the course of
the disease. 

 Our IgX  PLEX CHEX Technology  

        Our IgX  PLEX CHEX technology provides multiple in-microarray checks to ensure that the test has been completed without system, control,
calibration
or microarray-related errors. These tests reduce errors that are common to microtiter and microarray tests. 

        Our
proprietary multiplex assay development processes and microarray manufacturing capabilities, combined with our automated instruments, are designed to significantly reduce the
complexity and cost to our customers to commercialize microarray tests using their own biomarkers. Customers with a need to perform
large numbers of experiments may benefit from the use of our microarrays in their screening and development programs when traditional methods may be too onerous due to the large number of single tests
that would be required. 

 Our Key Competitive Strengths  

        We believe that our key competitive strengths include the following: 

	•
	Only FDA Cleared, Fully-Automated Microarray Processing
System.  We have received marketing clearance from the FDA, a Canadian regulatory medical device licence, and have CE marked our
SQiDworks instrument system. SQiDworks is the only system for automatically processing, analyzing and providing test results in protein-based and antibody-based microarrays to achieve these regulatory
clearances.   

	•
	Fully-Integrated, High-Throughput Solution Dramatically
Reduces Workflow and Cost.  Our proprietary microarray tests and fully-automated instruments are designed to significantly simplify
antigen, protein 

13

 

and
antibody workflow, increase throughput and reduce costs, all while providing excellent data quality. For example, competing systems require hundreds of steps to produce the same number of test
results as can be produced by our SQiDworks fully-integrated diagnostics system in five steps.  

	•
	Expertise in Microarray Assay
Development.  We have clinically validated development experience and have created processes, systems and development algorithms to
simplify the commercialization of our products. We believe our expertise will reduce the time required to complete the commercial development of our pipeline products. We also believe that our
experience can be applied to RUO products to allow us to commercialize our own and other's content in significantly less time than our competition.   

	•
	Focus on Penetrating Existing Markets that Are Technically Challenging
and Have Established Reimbursement.  We focus on disease testing markets that have existing reimbursement and payment programs in place,
which allows us to quickly bring our products into established markets. Additionally, antigen, protein and antibody multiplex tests are more technically challenging to develop, which may restrict
others from easily entering these markets.   

	•
	Partnerships with Leading
Institutions.  We have entered into agreements with leading institutions and healthcare providers to collaborate with us in developing
and validating our assays including providing us with access to approximately 10,800 clinically validated patient blood samples.   

	•
	Significant Intellectual Property
Portfolio.  Our intellectual property covers key areas of our commercial business as well as our pipeline, including microarray surfaces,
multiplexing, microarray analytics, and microarray processing. We have issued patents and pending patent applications that cover aspects of our microarray technology for analyzing, identifying and
quantifying analytes. We are actively seeking protection for our methods of achieving high-throughput quantitative analysis for our proprietary methods for making microarray substrates and
for the systems that carry out these methods for manufacturing microarray substrates. In the course of improving our products, from time to time we develop processes and systems that provide us with a
competitive advantage and the Company will keep such developments confidential. 

 Products  

 SQI Platforms  

 

 

									
	 
	 	 
	 	Regulatory Status 
	 
	 	Development

Status 
	Product

 
	 	Canada 	 	United States 	 	Europe 
	 SQiDworks
	 	Complete	 	Licensed	 	Cleared as a system with IgX PLEX RA	 	CE Marked
	 SQiDman
	 	Development RUO	 	Not Required — RUO	 	Not Required — RUO	 	Not Required — RUO
	 SQiDlite RUO
	 	In development	 	Not Required — RUO	 	Not Required — RUO	 	Not Required — RUO
	 SQiDlite IVD
	 	In development	 	To be filed	 	To be filed	 	To be filed

 

  SQiDworks  

        We have developed our fully-automated SQiDworks platform to enable laboratory customers to generate multiple patient test results with
less than one unit of traditional "test effort". "Test effort" refers to the number of steps required to perform a test using microtiter plate technology. 

        We
have received marketing clearance from the FDA, a medical device license from Health Canada, and have CE marked our SQiDworks instrument system. SQiDworks is the only fully-automated
microarray processing system to achieve these regulatory clearances. 

        Our
SQiDworks platform integrates a microfluidics station, an automated microarray scanner, our drying device and our proprietary processing and analytic software. 

        The
microfluidics station automatically performs sample handling and processing of the patient serum sample and prepares our IgX  PLEX microarray for scanning and analysis. 

14

 

        Our dryer technology dries the microarray surface, which uniformly enhances the signal to noise ratios of our microarrays. The microarray scanner reads the various IgX  PLEX
microarray devices. 

        Our
proprietary software uses complex algorithms to locate the array of spots containing reagents and to process the spots to measure each of the biomarkers of interest. This measurement
can be either qualitative or quantitative. 

 SQI Assays  

        Our four "cleared" or "approved" assays, two for rheumatoid arthritis and two for celiac, test for two of the more common autoimmune
diseases. Rheumatoid arthritis is a chronic inflammatory disease, the cause of which is unknown. The incidence of rheumatoid arthritis in North America is 1.4 cases per 100,000 in men
and 3.6 cases per 100,000 in women. The prevalence of rheumatoid arthritis is approximately 2% world wide. It is estimated that total size of the patient market in the
United States for rheumatoid arthritis diagnostic testing for 2010 was approximately six million patients. Celiac is an inherited autoimmune disorder that affects the digestive process of the
small intestine. It is estimated that the total size of the patient market in the United States for celiac diagnostic testing for 2010 was approximately 3.5 million patients. 

        Our
currently cleared or approved assays are as follows: 

 

 

									
	 
	 	 
	 	Clearance/Approval Status 
	 
	 	Development

Status 
	Product

 
	 	Canada 	 	United States 	 	Europe 
	 IgX PLEX RA

(Qualitative)
	 	Complete	 	Licensed	 	Cleared	 	N/A
	 IgX PLEX RA*

(Quantitative)
	 	Complete	 	Licensed	 	To be filed	 	CE Marked
	 IgX PLEX Celiac

(Qualitative)
	 	Complete	 	Licensed	 	Cleared	 	N/A
	 IgX PLEX Celiac

(Quantitative)
	 	Complete	 	Licensed	 	To be filed	 	CE Marked

 

 

	*
	Marketed
in Canada under the name "QuantiSpot Rheumatoid Arthritis" 

 

         We also have IgX  PLEX Lupus, IgX  PLEX Vasculitis and IgX  PLEX TNF products in the development stage and IgX  PLEX IBD/Crohn's and IgX  PLEX Antiphospholipid Syndrome ("APS")
products at the proof of concept stage. We also have rheumatoid
arthritis and celiac assays with greater sensitivity that measure additional biomarkers in development. 

        The
table below sets out estimates by Frost and Sullivan of the total number of patients in the United States who required diagnostic testing for diseases for which we are
developing diagnostic tests. 

 

 

														
	Autoimmune Segment

 
	 	Lupus 	 	Vasculitis 	 	Anti-TNF 	 	IBD/Crohn's 	 
	 Estimated Total Patient Market 2010 (US)
	 	 	5,000,000	 	 	400,000	 	 	3,100,000	 	 	550,000	 

 

  Research and Development  

        We have assembled an experienced research and development team at our Toronto facility with the scientific, microarray printing,
immunoassay, engineering, software, and process development expertise that we believe is necessary to grow our business. 

 Platform Development  

        SQiDman is our small semi-automated platform that we are commercialising for RUO purposes, and SQiDlite is our
fully-automated, bench-top diagnostic platform. 

         SQiDlite.    Our engineering development team is currently focused on the near term delivery of SQiDlite, our fully-automated, bench-top
diagnostic platform. This platform will be a fully-automated microarray 

15

 

processing
and analytic platform. We expect that SQiDlite will be able to process multiple sizes of microarray devices from single eight-well strips up to a single 96-well
microarray plate. 

        SQiDlite
is designed to serve the following markets: 

	•
	IVD Customers who wish to run IgXPLEX assays in flexible batch sizes up
to and including 96 patients per test kit.  We believe that many hospitals and other laboratories would benefit from SQiDlite's
more flexible batch size capability. SQiDlite is designed to run tests in volumes per run of eight to 96 patients in multiples of eight. We believe that a platform that allows for scalable
testing volumes for our assays would increase the number of our potential hospital customers in North America from the largest 1,000 to the largest 5,000 by diagnostic testing volume.  

	•
	Customers who seek a customizable automated microarray analyzer for RUO
purposes. We believe that many RUO customers would benefit from an automated microarray analyzer that can be used in a configurable manner to optimize
the development of assays. However, once assays are developed, many RUO customers seek to "lock" the settings to prevent modifications by the platform's operator. Our SQiDlite platform has been
designed to accommodate these RUO customers and provide this functionality. 

         SQiDman.    We are currently commercializing SQiDman on a pilot basis. SQiDman, our small semi-automated platform for processing
microarrays, is intended to be used by research customers or development partners for RUO purposes in the microarray development process. We currently use SQiDman systems for in-house
development and quality control processes. We expect the full commercial launch of SQiDman for RUO purposes in late 2011, following the enhancement of its user interface software. 

 Microarray Assay Development  

        The largest component of our current research and development efforts is microarray development. We plan to continue to focus on the
commercialization of microarray content that can be run by our customers on our diagnostic platforms. Our research and development efforts are focused on the following areas: 

         Autoimmune Disease.    We have a broad menu of autoimmune disease tests in our microarray development pipeline to augment our current
product offerings.
For example, in addition to our products for which we have marketing clearance or approval, we have IgX PLEX Vasculitis, IgX  PLEX Lupus, and IgX PLEX TNF products in the development stage and IgX  PLEX IBD/Crohn's and IgX PLEX APS at the proof of concept stage. Additionally, we have
rheumatoid
arthritis and celiac assays with greater sensitivity that measure additional biomarkers in development. See "— SQI Assays" for a description of the markets for the autoimmune
disease tests in our microarray development pipeline. 

        Infectious Disease.    We plan to develop tests in the area of infectious disease. Infectious disease panels leverage our strengths in
multiplexing,
antibodies and high-throughput diagnostic systems. We have scientists and assay development specialists with experience in infectious disease assay development. 

         Allergen Testing.    Allergen tests are very similar to, and depend upon many of the same technological advances as, autoimmune disease
tests. Because
allergen panels have large numbers of biomarkers, we believe this is an excellent area of opportunity to apply our multiplexing and microarray technology. 

         Custom Assay Development and Print Services.    We plan to add assay design and print services to our product offerings. This expansion is
intended to
enable our laboratory and diagnostic customers to expand their use of our platforms by converting their content to microarrays. We believe that applying our in-house processes and systems
to develop microarray formatted tests incorporating customers' content will allow them to reduce their assay costs with less development risk and effort by purchasing their microarrays and development
services directly from us. For example, our customers will be able to add requested target biomarkers to an existing panel of biomarkers or they may request an entire panel of protein-based or
antibody-based biomarkers to be developed into a RUO microarray that they may use as a lab-developed test. 

16

 

  

	(1)
	Approved
or cleared in the U.S. and Canada.

	(2)
	Approved
or cleared in Canada and Europe.

	(3)
	Development
status for clearance in the U.S. 

 Our Strategy  

        Our goal is to become an industry leader in the development and commercialization of microarray and multiplexing IVD medical systems.
We intend to accomplish this goal through: 

	•
	Product development
efforts.  We intend to continue to focus our research and development on high-volume, high-margin, multiplexed
tests for diseases for which there are existing tests that have reimbursement programs in place.   

	•
	Strategic market
penetration.  We have identified and are marketing our turnkey SQiDworks platform and approved assays to a specific group of laboratories
that process high volumes of tests and typically adopt new technologies to gain market share. Please see "— Sales and Marketing" for a description of our target laboratories.  

	•
	Leveraging our core technology and expertise to access new markets and new
customers. Our technology and microarray development processes enable us to provide customized third party microarray formatted test development and
manufacturing services.   

	•
	Seeking partnerships and strategic
acquisitions.  We intend to continue to seek partnerships that will enable us to expand into new markets, broaden and deepen our lines of
business and develop and strengthen our relationships with our customers.   

	•
	Leading through
innovation.  We intend to continue our research and development in each of our lines of business in order to become the industry leader
in multiplexing microarrays. 

 Strategic Alliances  

        We have a number of collaboration agreements with leading global research and treatment institutes. These collaborations improve our
ability to develop products by providing us with access to patient serum required for assay development, verification of products in development and final product clinical validation. 

17

 

        The
following table provides an overview of our partnering collaborations and the relevant pipeline product as at June 15, 2011: 

 

 

					
	Partner Institute

 
	 	Pipeline Product 	 	Purpose 
	 Cleveland Clinic
	 	Rheumatoid arthritis, IBD	 	Serum Samples

Clinical Validation

Collaboration
	 Beth Israel Deaconess Medical Center
	 	 Celiac, anti-TNF
	 	 Serum Samples

Collaboration / Publication

	 Hospital Clinic De Barcelona, Spain
	 	 Vasculitis
	 	 Serum Samples

Collaboration / Publication

	 University Hospital Maastricht, The Netherlands
	 	 Vasculitis
	 	 Serum Samples

Collaboration

	 The University of North Carolina at Chapel Hill
	 	 Vasculitis
	 	 Collaboration

Serum Samples

Clinical Validation

 

         We
collaborate with these partners to assist our development of new candidate biomarkers for future tests and intend to continue to seek additional alliances and partnerships. We have
been active in strategically publishing our progress and successes both alone and in collaboration with certain of our partners. 

 Sales and Marketing  

        We currently have a three-person marketing team. Our marketing efforts are focused on generating sales of our currently cleared or
approved system, which includes SQiDworks, IgX PLEX RA and IgX PLEX Celiac, to targeted,
high-volume laboratories in North America and Europe. 

        We
have identified the 400 largest laboratories, by testing volume, of the approximately 14,000 laboratories that provide blood testing services in North America and a
select group of approximately 30 European laboratories. We believe this group contains laboratories that would readily adopt new technologies, look to obtain an economic advantage over their
competitors, and attempt to increase their market share of diagnostic testing services. We believe that this initial target group has sufficient testing volume to support the use of SQiDworks, our
currently cleared or approved tests, and the tests that we anticipated to be cleared or approved by the end of 2011. We use various marketing strategies to provide incentives to the laboratories in
our initial target group that are among the first to adopt our technology. As we expand our test menu, we intend to broaden our target market and reduce the incentives provided to the early adopters
of our products. 

 Customers  

        We focus on two customer markets: 

	•
	Diagnostic Markets — this market
consists of reference and other diagnostic laboratories that provide for-profit diagnostic blood tests. 

Customers
in this market seek to purchase a full diagnostics solution, including automated platforms and IVD assays. These customers sell the results produced by running our IVD assays on our
automated platforms. In addition, customers in this market seek to purchase automated platforms and RUO assays that they intend to convert into lab-developed tests that incorporate their
biomarkers. These customers would run these lab-developed tests on our automated platforms and sell the results to their customers.  

	•
	Life Sciences Markets — this market
consists of customers seeking to commercialize their biomarkers as turnkey multiplexed products delivered by our contract development and manufacturing services. The customers in this market are
expected to buy our automated platform and consumable microarray test kits, and to pay a royalty to us on their sales. 

18

 

        There
are two types of customers in the life sciences markets: 

	•
	Contract Manufacturing and Development
Customers — these customers seek expertise for pilot and scale up microarray printing, and have needs in the molecular or protein/antibody
areas; and   

	•
	OEM customers — these customers seek full contract
development and manufacturing services to commercialize biomarkers owned by them and seek high-throughput automated microarray analyzers to sell through their channels. 

 Manufacturing  

        Our manufacturing facility is located in Toronto, Canada. We manufacture all of our microarray kits for commercial sale and internal
research and development in our facility. 

        We
operate a "current good manufacturing practices", or "cGMP", facility that has been certified ISO 13485:2003 compliant, which enables us to meet both regulatory requirements
and customer expectations. This is an international standard developed by the International Organization for Standardization that specifies the requirements for a quality management system for
organizations providing medical devices and related services. Our microarray production facility is operated to ISO Class 7 clean room specifications, commonly referred to as a
Class 10,000 operating level, which defines the maximum level of particles permitted per square meter. 

        Based
on our microarray manufacturing forecasts, we expect that there is adequate space in the current location to expand our manufacturing capacity to meet our expected needs until the
end of 2012. Until a facility upgrade is completed, we intend to undertake equipment upgrades to ensure sufficient manufacturing capacity to meet our expected requirements for commercial sales and our
internal validation studies until the end of 2012. 

        To
manufacture consumable tests, we acquire raw materials and custom molecules for our assays from well-established vendors who are either ISO certified or who have an
established quality system. Each incoming reagent ingredient undergoes quality testing as required and scrutiny before being released to the manufacturing unit, and the reagent ingredients are then
incorporated into finished goods as an IgX PLEX kit. Each kit contains the printed diagnostic array and several self-contained wet reagents
that are loaded into the SQiDworks platform prior to use by the customer. We have been producing products suitable for validation studies since the beginning of 2007. 

        Certain
key components of our SQiDworks platform are manufactured by third parties in FDA or ISO certified facilities and we manufacture one component. We assemble the components and
deliver them to our customers, where they undergo a series of quality acceptance tests. 

 Competition  

        We compete with both established and development-stage life sciences companies that design, manufacture and market basic ELISA
technology, lab automation products or multiplexing technologies. For example, companies such as INOVA Diagnostics, Inc., Phadia AB, Axis-Shield plc and Hycor
Biomedical, Inc. have immunoassay products based on basic ELISA technology. Companies such as Roche Diagnostics Corporation, bioMérieux SA, Siemens AG and Abbott
Laboratories Inc. provide laboratory automation technology. Companies such as Luminex Corporation and Bio-Rad Laboratories Inc. also provide bead-based
multiplexing technology. These companies provide products that compete in certain segments in which we sell our products. In addition, a number of other companies and academic groups are in the
process of developing novel technologies for life science markets. 

 Intellectual Property Strategy and Position  

        Our core intellectual property consists of patents that cover the following: 

	•
	multiplexed qualification of antigens and antibodies;   

	•
	internal (in-array) calibration; and   

	•
	methods to create diagnostic level spot morphology. 

19

 

        We
originated our core technology. Our patent strategy is to seek broad patent protection on new developments in microarray technology, tests and systems and then later file patent
applications covering new implementations of the technology and new microarray platforms utilizing the technology. As these technologies are implemented and tested, we file new patent applications
covering scientific methodologies enabled by our technology. 

        We
have developed our own portfolio of issued patents, patent applications and design patents directed to our methodologies, commercial products and technologies in development. For our
core technology relating to multiplexed qualification of antigens and antibodies and internal (in-array) calibration, we have obtained issued patents and approvals in certain jurisdictions
from the patent family having the title "Method to Measure Dynamic Internal Calibration True Dose Response Curves". This patent family is directed to our calibration technology that adjusts each
microarray for every test, which reduces the variability that may result from environmental factors or from the use of external calibrators. Other patent applications are currently pending. Patents
issuing from this patent family will be in force until July 20, 2025, provided that all maintenance fees are paid. 

        We
have also obtained either an issued patent or an allowance in some jurisdictions directed to our core technology relating to methods to create diagnostic level spot morphology. The
patent family for this core technology has the title "Method and Device to Optimize Analyte and Antibody Substrate Binding by Least Energy Adsorption". The patent family is directed to the use of
specialty surface treatments and surface coating process means that can create microarrays with consistent spot characteristics and limited background noise (in other words, with high signal to
noise ratios). Other patent applications are currently pending. Patents issuing from this patent family will be in force until July 20, 2025, provided that all maintenance fees are paid. 

        We
have filed patent applications that are currently pending in several jurisdictions directed to our qualitative and quantitative rheumatoid arthritis assays. In addition, patent
applications are pending in several jurisdictions directed to our products and methodologies including patent families entitled "Method for Double-Dip Substrate Spin Optimization of Coated
Micro-Array Supports", "Method and Device to Remove Fluid and Vapor", "Array Fluorescence Equalization Method", "Methods for Multiplex Analyte Detection and Quantification" and "Multiplex Microarrays
and Methods for Quantification of Analytes". 

 Government Regulation  

        We believe that our major markets are the United States, Canada and the European Union. The following describes the regulatory
clearance or approval process for diagnostic systems in each of those jurisdictions. 

 United States  

 Research Use Only  

        "Research use only" components are those components in the laboratory research phase of development that are not represented as
effective IVD products. These components must be labelled "For Research Use Only. Not for use in diagnostic procedures." These components are exempt from regulatory oversight in the
United States. Manufacturers frequently sell these components to laboratories certified under the Clinical Laboratory Improvement Amendments, or "CLIA", which are the United States
federal regulatory standards that apply to clinical laboratory testing performed on human specimens in the United States with certain exceptions, including clinical trials and
basic research. 

 Lab-Developed Tests  

        CLIA-compliant labs frequently develop and validate an assay from RUO components, sold to them by manufacturers, but the
lab must validate these tests and assume all liability for use on patient samples. These tests are regulated as lab-developed tests. 

 Diagnostic Tests  

        Diagnostic tests or assays, known as "in vitro diagnostic", or "IVD", products by the
FDA, are those reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including a 

20

 

determination
of a person's state of health, in order to cure, mitigate, treat or prevent disease or its sequelae. These tests are intended for use in the collection, preparation and examination of
specimens taken from the human body. 

        Diagnostic
tests are classified into one of three categories for FDA clearance or market approval. These categories are based on the degree of risk they pose to humans and their
importance in preventing impairment in human health. 

        All
IVD tests are subject to the following "general" requirements or controls, as well as, in the case of Class II and Class III diagnostic tests, additional requirements
(except where a particular device is expressly exempt from one or more of such requirements). General controls include: 

	•
	Registering the manufacturer with the FDA;   

	•
	Listing the product to be marketed with the FDA;   

	•
	Manufacturing the products in accordance with quality systems regulation (also known as current good manufacturing
practices);   

	•
	Labelling the test in accordance with labelling regulations;   

	•
	Submitting a pre-market notification (also known as a "510(k)") before marketing a test; and  

	•
	Reporting of adverse events and product recalls (corrections and removal). 

Class I 

        Class I
tests are subject to the least regulatory control as they present minimal potential for harm to the user. Most Class I devices and IVD
products are exempt from the pre-market notification and/or good manufacturing practices regulation. Examples of Class I IVD products include pregnancy or cholesterol tests. 

Class II 

        The
FDA defines Class II test as those for which "general controls" alone are insufficient to assure safety and effectiveness, and existing methods are
available to provide such assurances. In addition to complying with general controls, Class II devices are also subject to special controls. 

        Class II
tests often require pre-market notification under the FDA's 501(k) process, in connection with which the manufacturer submits data to the FDA to demonstrate
that its test is substantially equivalent to a legally marketed test (known as a "predicate" test). 

        Special
controls may include special labelling requirements, mandatory performance standards and post-market monitoring. Examples of Class II tests include most blood
tests, such as blood tests for rheumatoid arthritis, vasculitis, lupus and other immunological tests. 

Class III 

        Class III
is the most stringent regulatory category for tests. Class III tests are those for which the FDA believes insufficient information
exists to assure safety and effectiveness solely through general or special controls. 

        Class III
devices are usually those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential,
unreasonable risk of illness or injury. 

        The
FDA typically requires "pre-market approval" for these tests to ensure the safety and effectiveness of Class III tests. This type of approval would require the
submission and FDA review of clinical data to assess the safety and effectiveness of the test. 

        Examples
of Class III tests include tests for the diagnosis of many infectious diseases and cancer. 

21

 

 European Economic Area  

        The European Economic Area, which consists of the 27 member states of the European Union and the European Free Trade Association
countries of Iceland, Norway, Switzerland and Liechtenstein, requires what is called "CE" approval (the letters "CE" stand for "conformité Européenne" ("European
Conformity") for, among other things, IVD tests). Under the CE regulations, a manufacturer does a preliminary self-assessment to determine whether the products comply with all relevant
legislative requirements. At its most basic, the manufacturer must do a conformity assessment, set up a technical file and sign an EC declaration of conformity. This documentation must be made
available to authorities upon request. The relevant European Union directive may also require that the product be examined by a conformity assessment body. 

        We
have completed CE marking for our IgX PLEX RA quantitative assay, IgX PLEX Celiac quantitative assay, and the SQiDworks platform, which
allows us to market these assays and SQiDworks platform in the European Union. We must also implement and maintain an ISO quality management system. We received our initial ISO 13485
certification in June 2008 and have maintained this certification to date. 

        As
in the United States, components sold without any representation of performance claims may be labelled for "research use only," and are exempt from regulatory oversight in the
European Union. 

 Canada  

        The Canadian Health Protection Branch regulatory regime requires approvals and submissions similar in timing and scope to European
Union CE approvals. The Medical Devices Regulations (the Regulations), promulgated under the Food and Drugs
Act (Canada), set out, among other things, the requirements for the licensing of an "in vitro diagnostic device" or "IVDD".  In vitro diagnostic devices include reagents, assays and equipment used for examining specimens taken from the body. IVDDs are designated as
Class I, II, III and IV, based on the degree of risk associated with their use. For example, a blood test that detects bacterial meningitis is categorized as a Class III IVDD
because of the risk that a false-negative test result may cause death or long-term disability due to delayed diagnosis. Class IV IVDDs include donor screening tests for
transmissible viruses such as HIV and hepatitis, which present a high public health risk. 

        For
Class I IVDDs, all that is required is an establishment licence to manufacture the IVDD. For Class II, III and IV IVDDs, the Medical Devices Regulations require
the IVDDs to meet ISO standard 13485:2003, which provides both design and manufacturing standards. 

        An
application for a Class II medical device includes, in addition to information regarding the manufacturer and specific document,
the following: 

	•
	a description of the medical conditions, purposes and uses for which the device is manufactured, sold
or represented;   

	•
	a list of the standards complied with in the manufacture of the device to satisfy the safety and effectiveness
requirements;   

	•
	an attestation by a senior official of the manufacturer that the manufacturer has objective evidence to establish that the
device meets the safety and effectiveness requirements;   

	•
	an attestation by a senior official of the manufacturer that the device label meets the applicable labelling requirements
of the Regulations;   

	•
	in the case of a near patient in vitro diagnostic device, an attestation
by a senior official of the manufacturer that investigational testing has been conducted on the device using human subjects representative of the intended users and under conditions similar to the
conditions of use; and   

	•
	a copy of the quality management system certificate certifying that the quality management system under which the device
is manufactured satisfies National Standard of Canada CAN/CSA-ISO 13485:03, Medical devices — Quality management
systems — Requirements for regulatory purposes. 

        As
in the United States and Europe, components sold without any representation of performance claims may be labelled for "research use only," and are exempt from regulatory
oversight in Canada. 

22

 

 Approvals/Clearances  

 Health Canada  

        We have received licenses for all applications which have been made to Health Canada to date as listed in the following table. 

 

 

									
	Catalog Number 	 	Product

 
	 	Medical Device License 	 	Date of Issuance

 

	 	10005	 	QuantiSpot Rheumatoid Arthritis Assay*	 	 	78512	 	November 2008
	 	10105	 	IgX PLEX Rheumatoid Arthritis Qualitative Assay	 	 	81016	 	October 2009
	 	10505	 	IgX PLEX Celiac Qualitative Assay	 	 	83945	 	September 2010
	 	10515	 	IgX PLEX Celiac Panel*	 	 	85930	 	April 2011
	 	01003	 	SQiDworks Diagnostics Platform	 	 	78513	 	November 2008

 

 

	*
	Quantitative
assays 

 

  United States  

        Our 510(k) submission for IgX PLEX Rheumatoid Arthritis Qualitative Assay and SQiDworks Diagnostics Platform was cleared by the FDA in
October 2009 and our 510(k) submission for IgX PLEX Celiac Qualitative Assay and SQiDworks Diagnostics Platform was cleared by the FDA in June 2011. 

 European Union  

        Our IgX PLEX Celiac quantitative assay (Catalog #10515), IgX PLEX RA quantitative assay (Catalog #10005) and SQiDworks Diagnostics
Platform (Catalog #01004) have been CE marked and registered with the competent authority for our authorized representative. 

        Specific
registrations for each product will be made with the notified body of each country in which commercialization is anticipated once applicable label translations have
been completed. 

 Employees  

        As of May 31, 2011, we had 54 employees, of which three were in sales and marketing, 31 were in research and
development, 14 were in manufacturing and operations and six were in administration. Our employees have specialized knowledge in areas such as multiplexing, immunology, microarray design and
manufacture, assay development, systems engineering and medical-systems sales and servicing. 

        We
have never experienced a work stoppage or other labour disturbance. To our knowledge, none of our employees belongs to, or is represented by, a labour union. 

 RISK FACTORS  

        An investment in our common shares involves a number of risks. In addition to the other information contained
in this Annual Information Form and in the documents incorporated by reference into this Annual Information Form, including our consolidated financial statements and related notes, you should give
careful consideration to the following risk factors. Any of the matters highlighted in these risk factors could have a material adverse effect on our business, results of operations and financial
condition, causing an investor to lose all, or part of, its, his or her investment.

        The
risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are not aware of or focused upon, or that we currently deem to be
immaterial, may also impair our business operations and cause the trading price of our common shares to decline. 

23

 

 Risks Related to Our Business and Strategy  

 We have incurred losses since inception, and we expect to continue to incur losses for the foreseeable future.  

        We have a limited operating history and have incurred significant losses in each fiscal year since our inception, including net losses
of $3.8 million, $5.9 million, $8.1 million and $4.1 million during fiscal 2008, 2009, 2010 and the six months ended March 31, 2011, respectively. As of
March 31, 2011, we had an accumulated deficit of $37.6 million. These losses have resulted principally from costs incurred in our research and development programs and from our selling,
general and administrative expenses. We expect to continue to incur operating and net losses and negative cash flow from operations, which may increase, for the foreseeable future due in part to
anticipated increases in expenses for research and product development and expansion of our sales and marketing capabilities. We anticipate that our business will generate operating losses until we
successfully implement our commercial development strategy and generate significant additional revenues to support our level of operating expenses. Because of the numerous risks and uncertainties
associated with our commercialization efforts and future product development, we are unable to predict when we will become profitable, and we may never become profitable. Even if we do achieve
profitability, we may not be able to sustain or increase our profitability. 

 Our future capital needs are uncertain and we may need to raise additional funds in the future, which may not be available on a timely basis or on commercially reasonably
terms.  

        We believe that our existing cash and cash equivalents, will be sufficient to meet our anticipated cash requirements for at least the
next 10 months. However, we may need to raise substantial additional capital to: 

	•
	expand the commercialization of our products;   

	•
	manufacture our platforms in advance of placing them with our customers;   

	•
	fund our operations; and   

	•
	further our research and development. 

        Our
future funding requirements will depend upon many factors, including: 

	•
	development of new and existing products;   

	•
	market acceptance of our products;   

	•
	the cost of our research and development activities;   

	•
	the cost of potential licensing of technologies patented by others;   

	•
	the cost of filing and prosecuting patent applications;   

	•
	the cost of defending, in litigation or otherwise, any claims that we infringe third party patents or violate other
intellectual property rights;   

	•
	the cost and timing of regulatory clearances or approvals;   

	•
	the cost and timing of establishing additional sales, marketing and distribution capabilities;   

	•
	the cost and timing of establishing additional technical support capabilities;   

	•
	the effect of competing technological and market developments; and   

	•
	the extent to which we acquire or invest in businesses, products and technologies, although we currently have no
commitments or agreements relating to any of these types of transactions. 

        If
we raise additional funds by issuing equity securities, our shareholders may experience dilution. Debt financing, if available, may involve covenants restricting our operations or our
ability to incur additional debt. Any debt or additional equity financing may contain terms that are not favourable to us or our shareholders. If we raise additional funds through collaboration and
licensing arrangements with third parties, it may be 

24

 

necessary
to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favourable to us. 

        If
we do not have, or if we are unable to timely obtain additional funds on acceptable terms, or at all, we may have to delay development or commercialization of our products or license
to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize. We also may have to liquidate some or all of our assets, reduce the scope of or
eliminate some or all of our development programs, reduce marketing, customer support or other resources devoted to our products, or cease operations. Any of these factors could harm our business,
financial condition and results of operations. 

 Market competition and technological advances of similar diagnostics products could reduce the attractiveness of our products or render them obsolete.  

        The markets for our products are characterized by rapidly changing technology, evolving industry standards, changes in customer needs,
emerging competition, new product introductions and strong price competition. We compete with both established and development stage companies, universities, research institutions, governmental
agencies and healthcare providers that design, manufacture and market similar diagnostic products. Many of our current competitors have significantly greater name recognition, greater financial and
human resources, broader product lines and product packages, larger sales forces, larger existing installed bases, larger intellectual property portfolios and greater experience and capabilities in
researching, developing and testing products, in obtaining FDA and other regulatory approvals or clearances, and in manufacturing, marketing and distribution, than we have. For example, companies such
as Bio-Rad Laboratories Inc., Phadia AB, Axis-Shield plc, and INOVA Diagnostics, Inc. have products that compete in certain segments of the market in which
we sell our products, including immunoassays. In addition, a number of other companies and academic groups are in the process of developing novel products and technologies for diagnostics markets. 

        Our
competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements. In light of these
advantages, even if our technology is more effective than the product or service offerings of our competitors, current or potential customers might accept competitive products and services in lieu of
purchasing our technology. We anticipate that we will face increased competition in the future as existing companies and competitors develop new or improved products and as new companies enter the
market with new technologies. We may not be able to compete effectively against these organizations. Increased competition is likely to result in pricing pressures, which could harm our sales,
profitability or market share. Our failure to compete effectively could materially and adversely affect our business, financial condition and results of operations. 

 If our products fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected.  

        We currently have one customer and our success depends, in part, upon our ability to develop and market products that are recognized
and accepted as reliable, accurate, timely and cost effective by physicians, lab technicians and administrators. Most of our potential customers already use expensive diagnostic products and systems
in their laboratories and may be reluctant to replace those systems. Market acceptance of our products and technologies will depend upon many factors, including our ability to provide a broad test
menu of assays to potential customers, and our ability to convince potential customers that our systems are an attractive cost- and time-saving alternative to existing
technologies. Compared to most competing technologies, our microarray assay technology is relatively new, and most potential customers have limited knowledge of, or experience with, our products.
Prior to adopting our microarray assay technology, some potential customers may need to devote time and effort to testing and validating our systems. Any failure of our systems to meet these customer
benchmarks could result in customers choosing to retain their existing systems or to purchase systems other than ours. 

25

 

 We are subject to complex regulatory compliance requirements and the failure to obtain, or the withdrawal of, regulatory clearance or approval for our products could
adversely affect our ability to market our products and/or require us to incur significant costs to comply with such requirements.  

        We operate in a highly regulated industry and we are subject to the authority of certain regulatory agencies, including Health Canada,
the FDA, European Conformity (CE) and applicable health authorities in other countries, with regard to the development, testing, manufacturing, marketing and sale of our diagnostic products. The
process of obtaining such clearances or approvals can be costly and time-consuming, and if we are unable to timely obtain or maintain regulatory clearances or approvals, it would have a
material adverse effect on our business. Clearance by regulatory authorities can be suspended or revoked, or we could be fined, based on a failure to continue to comply with applicable standards. Any
failure to obtain (or significant delay in obtaining) or maintain applicable regulatory clearances or approvals (or, to a lesser extent, approval of applicable health authorities in other
countries) for our new or existing products could materially affect our ability to market its products successfully and could therefore have a material adverse effect on our business. Additionally,
the authority of the regulatory agencies or the application of certain regulations may be expanded or otherwise changed in such a manner that would place additional regulatory burdens on us or our
customers. Such a change in our industry could have a material adverse effect on our business. 

        We
must manufacture products in compliance with regulatory requirements, in sufficient quantities and on a timely basis, while maintaining product quality and acceptable manufacturing
costs. If we or our suppliers are
unable to manufacture or contract for such capabilities on acceptable terms, our plans for commercialization could be materially adversely affected. 

        Our
manufacturing facilities are subject to periodic regulatory inspections by the regulatory agencies and these facilities are subject to quality standards requirements of the
applicable regulatory authorities. We, or our contractors, may not satisfy such regulatory or standards requirements, and any failure to do so may have a material adverse effect on our business,
financial condition and results of operations. 

 We may not be able to develop new products or enhance the capabilities of our existing diagnostics products to keep pace with rapidly changing technology and customer
requirements.  

        The field of diagnostics is characterized by rapidly changing and developing technologies that include new products that could render
our diagnostic processing equipment and consumable tests obsolete at any time and thereby adversely affect our financial condition and future prospects. Our success depends upon our ability to develop
new products with improved performance and cost effectiveness in existing and new markets. New technologies, techniques or products could emerge that might offer better combinations of price and
performance than our current or future product lines. It is critical to our success for us to anticipate changes in technology and customer requirements and to successfully introduce new, enhanced and
competitive technology to meet our prospective customers' needs on a timely basis. 

        Developing
and marketing new products and services will require us to incur substantial development costs and we may not have adequate resources available to be able to successfully
introduce new versions of, or enhancements to, our products. We cannot guarantee that we will be able to maintain technological advantages over emerging technologies in the future. While we plan to
continue to make improvements to our current and future cleared or approved and marketed diagnostic processing equipment and consumable tests, we may not be able to successfully implement these
improvements. If we fail to keep pace with emerging technologies, demand for our products will not grow, and our business, revenue, financial condition and operating results could suffer materially.
Even if we successfully implement some or all of these planned improvements, we cannot guarantee that potential customers will find our enhanced products to be an attractive alternative to existing
technologies, including our current products. 

 Research and development of diagnostic products requires significant testing and investment and may not result in commercially viable products within the timeline
anticipated, if at all.  

        New diagnostic products, and improvements to existing diagnostic products, require significant research, development, testing and
investment prior to any final commercialization. Our business depends upon the continued development and improvement of our existing products, our development of new products to serve 

26

 

existing
markets and our development of new products to create new markets and applications that were previously not practical with existing systems. We believe that the adoption of our platform by
potential customers depends, in part, upon our ability to provide a test menu of assays to potential customers. To date, we have obtained regulatory approval for only a few diagnostic assays. 

        We
intend to devote significant personnel and financial resources to research and development activities designed to advance the capabilities of our diagnostic technology and, in the
case of our IVD business, to obtain regulatory approval of additional assays. In the past, our product development projects have been delayed. We may have similar delays in the future, and we may not
obtain any benefits from our research and development activities. Any delay or failure by us to develop new products or enhance existing products would have a material adverse effect on our business
and results of operations. If we are unable to successfully develop these products, accomplish such improvements, receive applicable regulatory clearances or approvals, produce the products in
commercial quantities at reasonable costs, or successfully market the products, it would have a material adverse effect on our business and results of operations. Our long-term success
must be considered in light of the expenses, difficulties and delays frequently encountered in connection with the development of new technology and the competitive and highly regulated environment in
which we operate. 

 We may need additional capacity to meet our manufacturing needs at the end of 2012.  

        Based on our microarray manufacturing forecasts, we expect that there is adequate capacity in our current location to expand our
manufacturing capacity to meet our expected needs until the end of 2012. Until a facility upgrade is completed, we intend to undertake equipment upgrades to ensure sufficient manufacturing capacity to
meet our expected requirements for commercial sales and our internal validation studies until the end of 2012. Pending the contemplated upgrades to, or expansion of, our facility, we are leasing our
facility under short-term arrangements. We do not anticipate any requirement to relocate any of our operations. However, we may need to relocate our facility upon one months' notice from
our landlord. 

        Our
inability to obtain our required manufacturing space in a timely manner and on terms acceptable to us will result in delays which could have a material adverse effect on our
financial condition and results of operations. 

        Even
if we are able to enter into a lease for a new facility, we must also implement and maintain an international standard ISO quality management system for such new facility. Any delay
in implementing an ISO quality management system will have a material adverse effect on our financial condition and results of operations. 

 Our future success depends upon our ability to expand our customer base and introduce new products and services.  

        Our success will depend upon our ability to gain acceptance, and then increase our market share, among our customers, attract
additional customers outside of our initial target markets, and bring to market new products and services. Attracting new customers and introducing new products and services requires substantial time
and expense. For example, it may be difficult to identify, engage and market to customers who are unfamiliar with the benefits of our products and services. Any failure to establish and expand our
existing customer base or launch new products or services would adversely affect our ability to increase our revenues. 

 We have limited experience in marketing, selling and distributing our products, and we need to expand our internal and external sales and marketing force and distribution
capabilities to successfully commercialize and sell our products.  

        As we are in the early stages of commercializing and marketing our products, we have limited experience in marketing, selling and
distributing our products. We may not be able to market, sell and distribute our products effectively enough to support our planned growth. We intend to market, sell and distribute our products
directly through our own sales force in North America, Europe and elsewhere. Our future sales will depend in large part upon our ability to develop and substantially expand our direct sales force and
to increase the scope of our marketing efforts. 

27

 

        Our
products are technically complex and used for specialized applications. Our ability to market our products effectively will depend, in part, upon our ability to convince laboratories
that our products will deliver accurate patient results in less time and with significantly reduced labour, consumables and other
costs. As a result, we believe it is necessary to develop a direct sales force that includes people with specific scientific backgrounds and expertise and a marketing group with technical
sophistication. Competition for such employees is intense. We may not be able to attract and retain personnel, or be able to build an efficient and effective sales and marketing force, which could
negatively impact sales of our products, and reduce any future revenues and profitability. 

        If
our sales, marketing and distribution efforts are not successful, our technologies and products may not gain market acceptance, which would materially impact our business operations. 

 We rely on strategic partnerships for research and development and commercialization of our products.  

        We have entered into and may continue to enter into strategic partnerships with a number of medical institutions. For example, we have
entered into strategic agreements with the Cleveland Clinic, Beth Israel Deaconess Medical Center, Hospital Clinic De Barcelona, University Hospital Maastricht, and The University of North Carolina at
Chapel Hill. If any of our strategic partners were to change their business strategies or development priorities, they may no longer be willing or able to participate in such strategic partnerships
which could have a material adverse effect on the timing of our future development efforts. In addition, we may not control the strategic partnerships in which we participate. We may also have certain
obligations with regard to our strategic partnerships, in addition to the obligation to pay money, such as an obligation to publish the results of research. 

        If
any of our strategic partners terminate their relationship with us or fail to perform their obligations in a timely manner, or if we fail to perform our obligations in a timely
manner, the development or commercialization of our technology in potential products may be affected, delayed or terminated. 

 We depend upon key suppliers for some of the components and materials used in our platform technologies and our microarrays, and the loss of any of these suppliers could
harm our business.  

        We rely on key suppliers for certain components and materials used in our platform technologies, including our SQiDworks diagnostic
platform and our microarrays. We do not have agreements with these key suppliers to supply us with components in the future. The loss of any of these key suppliers would require significant time and
effort to locate and qualify an alternative source of supply. There are a limited number of suppliers who can manufacture the highly specialized equipment that forms a part of our SQiDworks
system. 

        Our
first set of assays being commercialized requires a highly specific mono-layer coating on the glass surface which is used to bond each of the microarray "spots". We have
worked closely with these manufacturers to extend the capabilities of their standard products to support the unique needs of our
platform technologies and microarray devices. Any change in any component that forms a part of our SQiDworks system will require additional testing to ensure that it performs in a substantially
similar manner to the existing component. 

        Our
reliance on these suppliers also subjects us to other risks that could harm our business, including the following: 

	•
	we may be subject to increased component costs;   

	•
	we may not be able to ensure that any component that we change performs in a substantially similar manner to the existing
component;   

	•
	we may not be able to obtain adequate supply in a timely manner or on commercially reasonable terms;  

	•
	our suppliers may make errors in manufacturing components that could negatively affect the efficacy of our systems or
cause delays in shipment of our systems; and   

	•
	our suppliers may encounter financial hardships unrelated to our demand for components, which could inhibit their ability
to fulfill our orders and meet our requirements. 

28

 

        We
may not be able to quickly establish additional or replacement suppliers, particularly for our single source components. Any interruption or delay in the supply of components or
materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our strategic partners and
future customers. 

 Future legislative or regulatory changes to the healthcare system, including reimbursement, may adversely affect our business.  

        The healthcare regulatory environments in the jurisdictions in which we operate and plan to operate may change in a way that restricts
our ability to market our diagnostic testing products due to medical coverage or reimbursement limits. Sales of our diagnostic systems will depend, in part, upon the extent to which the costs to
patients of such tests are paid by health maintenance, managed care, and similar healthcare management organizations, or reimbursed by government health payor administration authorities, private
health coverage insurers and other third party payors. These healthcare management organizations and third party payors are increasingly challenging the prices charged for medical products and
services. The containment of healthcare costs has become a priority of governments. Accordingly, our potential products may not be considered cost effective, and reimbursement to the ultimate patient
may not be available or sufficient to allow us to sell our products on a competitive basis. Legislation and regulations affecting reimbursement for our products may change at any time and in ways that
are difficult to predict and these changes may be adverse to us. For example, a reduction in U.S. Medicare, Medicaid or other third party payor reimbursements for diagnostic services could have
a negative effect on our operating results. In June 2011, the FDA issued draft guidance that sets forth the FDA's proposed interpretation of laws regarding the marketing of IVD products
labelled as RUO products that could be used for in vitro diagnostic purposes. Among other things, the draft guidance suggests that it is generally
inappropriate for a manufacturer to sell RUO products to clinical laboratories that the manufacturer knows, or has reason to know, use the products for clinical diagnostic uses. Given that the
guidance is in draft form and has only recently been issued by the FDA, it is not clear how the FDA will interpret this guidance. As a result, we cannot be certain what impact, if any this guidance
will have on our business. 

 We rely on certain key personnel and our ability to successfully grow our business would be adversely affected by their departure from our company.  

        Our performance depends substantially upon the performance of our senior management and key scientific and technical personnel,
including our Chief Executive Officer, Claude Ricks, our Chief Financial Officer, Andrew Morris, and our Chief Scientific Officer, Dr. Peter Lea. Retaining these key personnel and recruiting
additional qualified personnel in the future will be critical to our success. We believe there are only a limited number of individuals with the requisite skills to serve in many of our key positions.
Competition for qualified personnel in the diagnostics industry is intense and recruiting and retaining qualified personnel with experience in our industry is very difficult. We compete for key
personnel with other medical equipment and software manufacturers and technology companies, as well as universities and research institutions. 

        If
we are unable to attract and retain skilled and experienced personnel, or if we lose the services of any member of our senior management or our scientific or technical staff, we could
experience significant delays in, or we could be unable to, complete the development and commercialization of our products or achieve our other business objectives, and such a development could
require our management to divert its attention to transition matters and identification of suitable replacements, if any. Such a development could have a material adverse effect on our business,
financial condition and results of operations. 

        We
do not maintain, and do not intend to obtain, key employee life insurance on any of our personnel. 

        A
portion of our compensation to our key employees is in the form of stock option grants. A prolonged decline in our share price could make it difficult for us to retain our employees
and recruit additional qualified personnel. 

 If we cannot provide quality technical support, we could lose customers and our operating results could suffer.  

        The placement of our products and the introduction of our technology into our customers' existing operations and on-going
customer support can be complex. Accordingly, we need highly trained technical 

29

 

support
personnel. To effectively support new customers, we will need to substantially expand our technical support staff. If we are unable to attract, train or retain the number of highly qualified
technical services personnel that our business will require, our business, financial condition and results of operations will suffer. 

 We may experience development or manufacturing problems or delays that could limit the growth of our revenue or increase our losses.  

        We have been developing our core technologies in our facilities in Toronto, Canada, which we believe has adequate space to expand the
manufacturing capacity to our expected needs for the foreseeable future. However, we may encounter unforeseen situations at this facility that would result in delays or shortfalls in our development
and production. In addition, our development and production processes and assembly methods may have to change to accommodate any significant future expansion of our manufacturing capacity. If we are
unable to keep up with development of or demand for our products, our revenue could be impaired, market acceptance for our products could be adversely affected and our customers might instead purchase
our competitors' products. Our inability to successfully manufacture our products would have a material adverse effect on our business, financial condition and results of operations. 

 Our products could have unknown defects or errors, which may give rise to claims against us and adversely affect market adoption of our systems.  

        Our products utilize complex technology applied on a small scale, and our systems may develop or contain undetected defects or errors.
As our production levels increase, material performance problems, defects or errors could arise. We may determine to correct any defects or errors in response to customer concerns, in order to
preserve customer relationships, and to help foster continued adoption and use of our systems. The costs incurred in correcting any defects or errors may be substantial and could adversely affect our
operating margins. 

        In
manufacturing our products, we depend upon third parties for the supply of various components. Many of these components require a significant degree of technical expertise to produce.
If our suppliers fail to produce components to specification, or if the suppliers, or we, use defective materials or workmanship in the manufacturing process, the reliability and performance of our
products will be compromised. 

        If
our products contain defects, we may experience: 

	•
	a failure to achieve market acceptance or expansion of our product sales;   

	•
	loss of customer orders and delay in order fulfillment;   

	•
	damage to our brand reputation;   

	•
	increased cost of our warranty program due to product repair or replacement;   

	•
	product recalls or replacements;   

	•
	inability to attract new customers;   

	•
	diversion of resources from our manufacturing and research and development departments into our service
department; and   

	•
	legal claims against us, including product liability claims, which could be costly and time consuming to defend and result
in substantial damages. 

        The
occurrence of any one or more of the foregoing could negatively affect our business, financial condition and results of operations. 

 We operate in an industry where there is the potential for substantial product liability claims that would cause us to incur significant costs, create adverse publicity
and/or prevent us from commercializing our products.  

        We may be subject to claims of personal injury and could become liable to clinical laboratories, hospitals, physicians and patients for
harm resulting from use of our products. We could suffer financial loss due to defects in our products, and such financial loss and potential litigation expenses could have a material adverse effect
on our business, financial condition and results of operations. If our product liability insurance is not adequate to 

30

 

cover
all claims or if we are unable to maintain such insurance at reasonable cost, it would have a material adverse effect on our business, financial condition and results of operations. 

 We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming
and costly.  

        Our research and development and manufacturing processes involve the controlled use of hazardous materials, including flammables,
toxics, corrosives and biologics. We maintain a level 2 biohazard laboratory (a laboratory that has established specific procedures for handling bacteria and viruses that may pose a risk
of mild disease in humans) and our operations produce hazardous biological and chemical waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury
from these materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials. We do not currently maintain separate environmental
liability coverage and any such contamination or discharge could result in significant cost to us in penalties, damages and suspension of our operations. 

 We may be unable to successfully manage fluctuations in revenue, which could impede our ability to successfully develop, market and sell our products.  

        Our quarterly and annual revenues may fluctuate due to several factors, including customer order patterns, the rate of acceptance of
our products, regulatory uncertainties or delays, costs and timing associated with business development activities, including potential licensing of technologies, and international market conditions.
The impact of one, or a combination of several, of these factors could have a significant adverse effect on our business, financial condition and results of operations. 

 Our future financial results may be adversely affected by foreign exchange fluctuations.  

        We expect that a significant portion of our future revenues will be denominated in U.S. and European currencies, and, therefore, we
will be subject to fluctuations in exchange rates. There is a risk that significant fluctuations in exchange rates would negatively affect our operating margins and would therefore have an adverse
effect on our future results of operations. 

 Risks Related to Intellectual Property  

 Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain.  

        Our commercial success depends in part upon our ability to protect our intellectual property and proprietary technologies. We rely on
patent protection, where appropriate and available, as well as a combination of copyright, trade secret and trademark laws, and nondisclosure, confidentiality and other contractual restrictions to
protect our proprietary technology. However, these legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Our
pending Canadian, U.S. and foreign patent applications may not issue as patents or may not issue in a form that will be sufficient to protect our proprietary technology and gain or
keep our competitive advantage. Any patents we have obtained or do obtain may be subject to re-examination, reissue, opposition or other administrative proceeding, or may be challenged in
litigation, and such challenges could result in a determination that the patent is invalid or unenforceable. In addition, competitors may be able to design alternative methods or devices that avoid
infringement of our patents. To the extent our intellectual property, including licensed intellectual property, offers inadequate protection, or is found to be invalid or unenforceable, we are exposed
to a greater risk of direct competition. If our intellectual property does not provide adequate protection against our competitors' products, our competitive position could be adversely affected, as
could our business, financial condition and results of operations. Both the patent application process and the process of managing patent disputes can be time consuming and expensive. Furthermore, the
laws of some foreign countries may not protect our intellectual property rights to the same extent as do the laws of Canada and the United States. 

31

 

        The patent positions of companies in the diagnostics industry can be highly uncertain and involve complex legal and factual questions for which important legal principles remain
unresolved. No consistent policy regarding the breadth of claims allowed in such companies' patents has emerged to date in Canada and the United States. The laws of some
non-Canadian countries do not protect intellectual property rights to the same extent as the laws of Canada, and many companies have encountered significant problems in protecting and
defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favour the enforcement of patents and other intellectual
property protection, which could make it difficult for us to stop the infringement of our patents. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost
and divert our efforts and attention from other aspects of our business. Changes in either the patent laws or in interpretations of patent laws in the United States, Canada or other countries
may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party patents.
For example: 

	•
	we might not have been the first to make the inventions covered by each of our pending patent applications;  

	•
	we might not have been the first to file patent applications for these inventions;   

	•
	others may independently develop similar or alternative products and technologies or duplicate any of our products and
technologies;   

	•
	it is possible that none of our pending patent applications will result in issued patents, and even if they issue as
patents, they may not provide a basis for commercially viable products, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties;  

	•
	we may not develop additional proprietary products and technologies that are patentable;  

	•
	the patents of others may have an adverse effect on our business; and   

	•
	we may fail to apply for patents on important products and technologies in a timely fashion or at all. 

        In
addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into confidentiality agreements and
intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful
protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such
unauthorized disclosure. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce
a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside Canada
and the United States may be less willing to protect trade secrets. 

 We may be involved in lawsuits to protect or enforce our patents and proprietary rights, to determine the scope, coverage and validity of others' proprietary rights, or to
defend against third party claims of intellectual property infringement that could require us to spend significant time and money and could prevent us from selling our products or services or impact
our share price.  

        The diagnostics industry relies heavily upon patented technology. We follow a patent program to protect our technology and take
precautions to avoid infringement against the technology of others. Litigation may be necessary for us to enforce our patent and proprietary rights and/or to determine the scope, coverage and validity
of others' proprietary rights. Litigation on these matters has been prevalent in our industry and we expect that this will continue. To determine the priority of inventions, we may have to initiate
and participate in interference proceedings declared by the Canadian Intellectual Property Office, the U.S. Patent and Trademark Office, and patent offices in other countries that could result
in substantial legal fees and could substantially affect the scope of our patent protection. Also, our intellectual property may be subject to significant administrative and litigation proceedings
such as invalidity, unenforceability, re-examination and opposition proceedings against our patents. The outcome of any litigation or other proceeding is inherently uncertain and might not
be favourable to us, and we might not be able to obtain licenses to technology that we require on 

32

 

commercially
acceptable terms or at all. We could therefore incur substantial costs related to royalty payments for licenses obtained from third parties. Further, we could encounter delays in product
introductions, or interruptions in product sales, as we develop alternative methods or products. 

        In
addition, if we resort to legal proceedings to enforce our intellectual property rights or to determine the validity, scope and coverage of the intellectual property or other
proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail. 

        Our
commercial success may depend in part upon our non-infringement of the patents or proprietary rights of third parties. Numerous significant intellectual property issues
have been litigated, and will likely continue to be litigated, between existing and new participants in the diagnostics market and competitors may assert that our products infringe their intellectual
property rights as part of a business strategy to impede our successful entry into that market. Third parties may assert that we are employing their proprietary technology without authorization. 

        In
addition, our competitors and others may have patents or may in the future obtain patents and claim that use of our products infringes these patents. As we move into new markets and
applications for our products, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means
to extract substantial license and royalty payments from us. 

        Patent
infringement suits can be expensive, lengthy and disruptive to business operations. We could incur substantial costs and divert the attention of our management and technical
personnel in prosecuting or
defending against any claims, and may harm our reputation. There can be no assurance that we will prevail in any suit initiated against us by third parties. Furthermore, parties making claims against
us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products, and could result in the award of substantial damages against us,
including treble damages and attorneys' fees and costs in the event that we are found to be a willful infringer of third party patents. 

        In
the event of a successful claim of infringement against us, we may be required to obtain one or more licenses from third parties, which we may not be able to obtain at a reasonable
cost, if at all. In addition, we could encounter delays in product introductions while we attempt to develop alternative methods or products to avoid infringing third party patents or proprietary
rights. Defense of any lawsuit or failure to obtain any required licenses on favourable terms could prevent us from commercializing our products, and the risk of a prohibition on the sale of any of
our products could adversely affect our ability to grow and gain market acceptance for our products. 

        Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other
interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common shares. 

        In
addition, our agreements with suppliers, customers, and other entities with whom we do business, may require us to defend or indemnify these parties to the extent they become involved
in infringement claims against us, including the claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we
determine it would be important to our business relationships. If we are required or agree to defend or indemnify any of these third parties in connection with any infringement claims, we could incur
significant costs and expenses that could adversely affect our business, financial condition or operating results. 

 We may in the future depend upon licensed technology to conduct our business. We might not control these technologies and any loss of our rights to them could in the future
prevent us from selling our products.  

        We may in the future rely on licenses in order to be able to use various proprietary technologies that become material to our business.
We might not own the patents that underlie these licenses. This may subject us to certain risks that might not be present if we develop the technology and intellectual property independently. 

33

 

        In
many potential third party licenses, we might not control the prosecution, maintenance, or filing of the patents to which we may in the future hold licenses, or the enforcement of
these patents against third parties. We cannot be certain that drafting and/or prosecution of the licensed patents by the licensors will be conducted in compliance with applicable laws and regulations
or will result in valid and enforceable patents and other intellectual property rights. As a result, we may depend upon the licensor to diligently pursue and prosecute these intellectual property
rights. The failure of the licensor to diligently pursue such protection could adversely affect our business and financial condition. 

        Our
rights to use the technology we might license may be subject to the validity of the owner's intellectual property rights. Enforcement of such licensed patents or defense of any
claims asserting the invalidity of these patents is often subject to the control or cooperation of our licensors. Legal action could be initiated against the owners of the intellectual property that
we may license. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent these other companies or institutions from continuing to license
intellectual property that we may need to operate our business. 

        Our
rights to use the technology we may in the future license are subject to the negotiation of, continuation of and compliance with the terms of those licenses. Specifically, license
agreements typically subject us to milestone obligations and royalty payments. Some of these obligations may be substantial and may obligate us to obtain certain regulatory clearances or approvals by
a specified date or exercise diligence in bringing potential products to market. The failure to meet these obligations typically results in the termination of the license and the loss of rights to the
technology. Any such termination could prevent us from marketing some or all of our products and could adversely affect our business, financial condition and results of operations. 

        Because
of the complexity of our products and the patents we may license, determining the scope of such licenses and related royalty obligations can be difficult and can lead to disputes
between us and the licensor. An unfavourable resolution of such a dispute could lead to an increase in the royalties payable pursuant to the license. If a licensor believed we were not paying the
royalties due under the license or were otherwise not in compliance with the terms of the license, the licensor might attempt to revoke the license. If such an attempt were successful, we might be
barred from producing and selling some or all of our products. 

        Finally,
many potential third party licenses of technology expire when the patents underlying the technology expire or at some period of time after expiration. As a result, our ability
to exploit and fully commercialize the licensed technology over time may be limited. This may adversely affect our business, financial condition and results of operations. 

 We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our employees' former employers.  

        Many of our employees were previously employed at universities or other life sciences companies, including our competitors or potential
competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other
proprietary information of their former employers. Litigation may be
necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key
research personnel or their work product could hamper or prevent our ability to commercialize potential products, which could severely harm our business. Even if we are successful in defending against
these claims, litigation could result in substantial costs and be a distraction to management. 

 Risks Related to Our Common Shares  

 We expect that our share price will fluctuate significantly, and you may not be able to resell your common shares at or above the current price.  

        Our common shares are listed for trading on the TSX Venture Exchange ("TSXV"). We
cannot predict the extent to which investor interest in our company will lead to the development of an active trading market on the TSXV, or how liquid that market might become. If an active trading
market does not develop, you may have difficulty selling any of our common shares that you buy. The market price of our common shares on the TSXV, 

34

 

like
the share prices of many publicly traded life sciences companies, has been highly volatile, and the trading price of our common shares may remain volatile in response to various factors, some of
which are beyond our control. These factors could include, for example: 

	•
	actual or anticipated quarterly variation in our results of operations or the results of our competitors;  

	•
	announcements by us or our competitors of technological innovations, new commercial products, significant contracts,
commercial relationships or capital commitments;   

	•
	developments or disputes concerning our intellectual property or other proprietary rights;   

	•
	commencement of, or our involvement in, litigation;   

	•
	market conditions in the diagnostics sector;   

	•
	regulatory developments in the U.S., Canada and other countries;   

	•
	failure to complete significant sales;   

	•
	issuance of new or changed securities analysts' reports or recommendations for our common shares;  

	•
	any future sales of our common shares or other securities;   

	•
	any major change to the composition of our board of directors or management; and   

	•
	general economic conditions and slow or negative growth of our markets. 

        The
stock market in general, and market prices for the securities of technology-based companies like ours in particular, have from time to time experienced volatility that often has been
unrelated to the operating performance of the underlying companies. A certain degree of stock price volatility can be attributed to being a newly public company. These broad market and industry
fluctuations may adversely affect the market price of our common shares, regardless of our operating performance. In several recent situations where the market price of an issuer's shares has been
volatile, holders of those shares have instituted securities class action litigation against the company that issued the shares. If any of our shareholders were to bring a
lawsuit against us, the defense and disposition of the lawsuit could be costly, and could divert the time and attention of our management and harm our operating results. 

 If securities or industry analysts do not publish research or publish unfavourable research about our business, our share price and trading volume could decline.  

        The trading market for our common shares will rely in part on the research and reports that equity research analysts may publish about
us and our business. We do not currently have and may never obtain research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common
shares, and such lack of research coverage may adversely affect the market price of our common shares. If we obtain equity research analyst coverage, we will not have any control over the analysts or
the content and opinions included in their reports. The price of our common shares could decline if one or more equity research analysts downgrade our common shares or issue other unfavourable
commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our common shares could decrease, which in turn
could cause our share price or trading volume to decline. 

 Our directors and executive officers will continue to have substantial control over us and could limit your ability to influence the outcome of key transactions, including
changes of control.  

        Our executive officers, directors and their affiliates beneficially own or control approximately 21.45% of our outstanding common
shares. Accordingly, these executive officers, directors and their affiliates, acting as a group, have substantial influence over the outcome of corporate actions requiring shareholder approval,
including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transactions or agreements. These shareholders may
also delay or prevent a change of control of our company, even if such a change of control would benefit our other shareholders. The significant 

35

 

concentration
of share ownership may adversely affect the trading price of our common shares due to investors' perception that conflicts of interest may exist or arise. 

 We have never paid dividends on our common shares, and we do not anticipate paying any cash dividends in the foreseeable future.  

        To date, we have not paid any dividends and do not expect to do so in the foreseeable future. We currently intend to retain all future
earnings for the operation and expansion of our business. Dividends on our common shares are declared at the discretion of our board of directors and will depend on our results of operations, capital
requirements, financial condition, prospects, contractual arrangements and other factors that our board determines is relevant. 

 
 

  DIVIDENDS AND DISTRIBUTIONS    
    

        To date, we have not paid any dividends and do not expect to do so in the foreseeable future. We currently intend to retain all future
earnings for the operation and expansion of our business. Dividends on our common shares are declared at the discretion of our board of directors and will depend on our results of operations, capital
requirements, financial condition, prospects, contractual arrangements and other factors that our board determines is relevant. 

 
 

  DESCRIPTION OF CAPITAL STRUCTURE    
    

 Common Shares  

        We are authorized to issue an unlimited number of common shares. The holders of common shares are entitled to one vote per share at
meetings of shareholders, to receive such dividends as declared by our board for directors and to receive the remaining property and assets of upon our dissolution or winding up. The common shares are
not subject to any future call or assessment and there are no pre-emptive, conversion or redemption rights attached to such shares. 

 Warrants  

        As of May 31, 2011, we had outstanding warrants to purchase an aggregate of 2,632,852 common shares at exercise prices
ranging from $1.90 per share to $5.00 per share. These warrants will expire at various times between December 4, 2011 and August 12, 2012. In the event of a distribution of dividends, a
stock split, a reorganization, a reclassification, a consolidation, or a similar event, each warrant provides for adjustment of the exercise price and the number of shares issuable
upon exercise. 

 Options  

        We maintain a stock option plan for the benefit of directors, officers, employees and consultants. The aggregate number of common
shares reserved for issuance under the plan, together with any other employee stock option plans, options for services and employee share purchase plans, may not exceed 10% of the issued and
outstanding common shares at the time of the option grant (on a non-diluted basis). Options granted pursuant to the plan must have terms not to exceed five years, and are granted at
an option price that may not be less than the fair market price at the time the options are granted. All options granted to individual optionees, other than consultants, generally vest in three equal
instalments over a period of 36 months. 

36

 
 
 

  MARKET FOR SECURITIES    
    

 Trading Price and Volume  

        Our common shares are listed and posted for trading on the TSXV under the symbol "SQD". The following table sets out, for the periods
indicated, the reported high and low sales prices and aggregate volume of trading of our common shares on the TSXV for the periods indicated. 

 2009  

 

 

											
	Month

 
	 	Volume

(#) 	 	High Trading

Price

(C$) 	 	Low Trading

Price

(C$) 	 
	 October
	 	 	105,441	 	 	2.50	 	 	1.81	 
	 November
	 	 	764,708	 	 	3.67	 	 	2.50	 
	 December
	 	 	179,564	 	 	3.00	 	 	2.40	 

 

  

 2010  

 

 

											
	Month

 
	 	Volume

(#) 	 	High Trading

Price

(C$) 	 	Low Trading

Price

(C$) 	 
	 January
	 	 	169,691	 	 	2.60	 	 	2.25	 
	 February
	 	 	438,181	 	 	2.40	 	 	2.12	 
	 March
	 	 	153,377	 	 	2.27	 	 	1.60	 
	 April
	 	 	315,620	 	 	2.47	 	 	2.21	 
	 May
	 	 	199,865	 	 	2.41	 	 	2.05	 
	 June
	 	 	1,097,152	 	 	2.47	 	 	2.00	 
	 July
	 	 	354,891	 	 	2.42	 	 	2.21	 
	 August
	 	 	644,310	 	 	3.13	 	 	2.30	 
	 September
	 	 	604,825	 	 	3.18	 	 	2.76	 
	 October
	 	 	744,468	 	 	2.97	 	 	2.65	 
	 November
	 	 	193,705	 	 	2.70	 	 	2.42	 
	 December
	 	 	104,220	 	 	2.75	 	 	2.50	 

 

  

 2011  

 

 

											
	Month

 
	 	Volume

(#) 	 	High Trading

Price

(C$) 	 	Low Trading

Price

(C$) 	 
	 January
	 	 	253,844	 	 	3.20	 	 	2.70	 
	 February
	 	 	442,792	 	 	3.42	 	 	2.90	 
	 March
	 	 	177,537	 	 	3.38	 	 	3.00	 
	 April
	 	 	100,731	 	 	3.25	 	 	2.95	 
	 May
	 	 	414,333	 	 	3.45	 	 	3.09	 
	 June(1)
	 	 	93,824	 	 	3.60	 	 	3.35	 

 

 

	(1)
	As
at market close on June 14, 2011. 

 

  Prior Sales  

 Common Shares  

        On August 12, 2010, pursuant to a private placement, we issued 2,280,000 units, each comprised of one common share and
one-half common share purchase warrant, at a price of $2.50 per unit, resulting in gross proceeds of $5,700,000. 

37

 

        On
December 4, 2009, pursuant to a private placement, we issued 2,398,104 units, each comprised of one common share and one-half common share purchase warrant,
at a price of $2.75 per unit, resulting in gross proceeds of $6,595,000. 

        Since
October 1, 2009, we have issued the following common shares upon the exercise of warrants. 

 

 

								
	Date of Issue

 
	 	Number of

Common Shares

Issued 	 	Purchase Price

per Common Share 	 
	 November 9, 2009
	 	 	5,000	 	 	$2.40	 
	 November 16, 2009
	 	 	1,563	 	 	$2.40	 
	 November 23, 2009
	 	 	2,500	 	 	$2.40	 
	 January 18, 2010
	 	 	13,288	 	 	$0.60	 
	 April 12, 2010
	 	 	30,000	 	 	$2.40	 
	 April 23, 2010
	 	 	186,205	 	 	$0.60	 
	 May 06, 2010
	 	 	101,000	 	 	$2.40	 
	 May 14, 2010
	 	 	65,000	 	 	$2.40	 
	 June 3, 2010
	 	 	194,200	 	 	$1.50	 
	 June 22, 2010
	 	 	15,000	 	 	$2.40	 
	 June 25, 2010
	 	 	217,500	 	 	$2.40	 
	 June 29, 2010
	 	 	139,000	 	 	$2.40	 
	 January 21, 2011
	 	 	106,520	 	 	$1.25	 

 

         Since
October 1, 2009, we have issued the following common shares upon the exercise of stock options. 

 

 

								
	Date of Issue

 
	 	Number of

Common Shares

Issued 	 	Exercise Price 	 
	 April 14, 2010
	 	 	141,670	 	 	$1.20	 
	 April 14, 2010
	 	 	166,670	 	 	$0.60	 
	 April 21, 2010
	 	 	5,000	 	 	$1.74	 
	 June 18, 2010
	 	 	16,667	 	 	$1.20	 
	 August 23, 2010
	 	 	10,000	 	 	$1.75	 
	 September 1, 2010
	 	 	10,000	 	 	$1.75	 
	 December 17, 2010
	 	 	7,500	 	 	$1.74	 
	 January 21, 2011
	 	 	2,500	 	 	$1.30	 
	 Feb 14, 2011
	 	 	8,334	 	 	$1.20	 
	 March 30, 2011
	 	 	30,000	 	 	$1.74	 
	 April 26, 2011
	 	 	33,334	 	 	$1.20	 

 

  Options  

        The following table sets forth the details for all options that we granted under our option plan during the 12-month period
prior to October 1, 2009. 

 

 

								
	Date of Grant

 
	 	Number of

Common Shares

Under

Options Granted 	 	Exercise Price 	 
	 November 4, 2009
	 	 	25,000	 	 	$3.26	 
	 February 22, 2010
	 	 	124,000	 	 	$2.25	 
	 May, 27, 2010
	 	 	60,000	 	 	$2.10	 
	 August 16, 2010
	 	 	175,000	 	 	$2.50	 
	 October 4, 2010
	 	 	100,000	 	 	$2.90	 
	 January 31, 2011
	 	 	75,000	 	 	$2.85	 

 

 38

 

 Warrants  

        The following table sets forth the details for all warrants that we issued since October 1, 2009. 

 

 

								
	Date of Issue

 
	 	Number of

Common Shares

Under

Warrants Granted 	 	Exercise Price 	 
	 December 4, 2009
	 	 	143,886	 	 	$2.75	 
	 December 4, 2010
	 	 	1,199,052	 	 	$4.00	 
	 August 12, 2010
	 	 	1,140,000	 	 	$5.00	 
	 August 12, 2010
	 	 	57,000	 	 	$2.50	 

 

  
 

  DIRECTORS AND OFFICERS    
    

        The following table sets forth the names, municipalities of residence, positions held with us and principal occupations of our
directors and executive officers and, if a director, the month and year in which the person became a director. Our directors hold office until the next annual meeting of our shareholders or until
their successors are appointed. 

 

 

										
	Name, Place of Residence and

Director Since (if applicable)

 
	 	Principal Occupation 	 	Number of Common

Shares Beneficially

Owned or Controlled 	 	Percentage of

Common Shares 	 
	Claude Ricks

Barrie, ON

May, 2007	 	Currently and since May 2007, Mr. Ricks has been the President, Chief Executive Officer and a director of the Company Prior to that, Mr. Ricks was the Chief Executive Officer of SQIDS.	 	 	1,992,157	 	 	6%	 
	Dr. Peter Lea

Toronto, ON

May, 2007	 	Currently and since May 2007, Dr. Lea has been the Chief Science Officer and a director of the Company. Prior to that, Dr. Lea was Chief Science Officer and director of SQIDS.	 	 	2,173,904	 	 	6%	 
	Eric Schneider (1) (2)

Waterloo, ON

May, 2007	 	Currently and for the past five years, Mr. Schneider is a partner in the law firm Miller Thomson LLP and its predecessors.	 	 	380,585	 	 	1%	 
	Saied Nadjafi (2)

Toronto, ON

May, 2007	 	Currently and for the past five years Mr. Nadjafi is an independent business man.	 	 	1,931,475	 	 	6%	 
	David Williams (1)

Toronto, ON

May, 2007	 	Currently and for the past five years, Mr. Williams is the President of Roxborough Holdings Limited, a Toronto based investment company.	 	 	477,225	 	 	1%	 
	Paul J. Mountain, (2)

Welland, ON

August, 2007	 	Currently and since August 2007, Mr. Mountain has been an independent consultant. Prior to that and since January 1990 Mr. Mountain was Vice President of Science and Technology at MDS Inc., a
Toronto-based diversified healthcare company.	 	 	Nil	 	 	—

	 

 

 39

 
 

 

										
	Name, Place of Residence and

Director Since (if applicable)

 
	 	Principal Occupation 	 	Number of Common

Shares Beneficially

Owned or Controlled 	 	Percentage of

Common Shares 	 
	Peter Winkley (1)

Mississauga, ON

November, 2007	 	Currently and since September 2010, Mr. Winkley is the Vice President and Chief Financial Officer of Algoma Capital Corporation. Prior to that, Mr. Winkley was the Chief Financial Officer of Therapure
Biopharma Inc. a Mississauga-based biologics contract manufacturer. Prior to this, Mr. Winkley was Vice-President, Corporate Finance at MDS Inc.	 	 	Nil	 	 	—	 
	Andrew Morris

Oakville, ON	 	Currently and since 2004, Mr. Morris is the Chief Financial Officer of the Company.	 	 	283,340	 	 	0.8%	 
	Catherine Smith

Toronto, ON	 	Currently and since January 2005, Ms. Smith is the Vice President, Technology of the Company.	 	 	42,168	 	 	0.1%	 
	Jaymie R. Sawyer

Thornhill, ON	 	Currently and since October 2010, Ms. Sawyer is the Vice President, R&D of the Company. Prior to that and since 2002, Ms. Sawyer was the Director, R&D at BD Biosciences	 	 	Nil	 	 	—

	 

 

 

	(1)
	Member
of the audit committee (the "Audit Committee") (appointed annually).

	(2)
	Member
of the compensation committee (the "Compensation Committee") (appointed annually). 

 

         As of June 15, 2011 as a group, our directors and executive officers beneficially owned, directly or indirectly, or exercised control over,
7,280,854 common shares, which represented 21.45% of the outstanding common shares. Additionally, as of June 15, 2011 as a group, our directors and executive officers beneficially owned,
directly or indirectly, or exercised control over, options to purchase up to 1,158,339 common shares. 

        Except
as disclosed below, each of our directors and executive officers has been engaged for five years in his present principal occupation or in other capacities with the company or
organization (or predecessor thereof) in which he currently holds his principal occupation. The information provided below has been provided to us by the individuals themselves and has not been
independently verified by us. 

 Board Committees  

        Our board of directors has established an Audit Committee and a Compensation Committee to assist the directors in efficiently carrying
out their responsibilities. 

 Audit Committee  

        Our board of directors has appointed an Audit Committee consisting of three directors, being Eric Schneider, David Williams and Peter
Winkley, the Chair of the Audit Committee all of whom are "financially literate" within the meaning of Multilateral Instrument 52-110 (Audit Committees) have accounting or related
financial expertise, and are "independent" within the meaning of applicable Canadian securities laws. The responsibilities and mandate of the Audit Committee are set out in an Audit Committee Charter.
The primary purposes of the Audit Committee are to: 

	(a)
	assist
the board's oversight of:

	(i)
	the
integrity of our financial statements and other financial reporting; 

40

 

	(ii)
	the
external auditor's qualifications and independence;

	(iii)
	the
performance of our internal audit functions and internal auditor, if and when one is appointed;

	(iv)
	our
compliance with legal and regulatory requirements; and

	(v)
	any
other matters as defined by the board;

	(b)
	manage,
on behalf of the shareholders, the relationship between us and the external auditors by:

	(i)
	recommending
to the board the nomination and remuneration of the external auditors;

	(ii)
	overseeing
the work of the external auditors for the purpose of preparing or issuing an auditor's report or performing other audit, review or attest
services for us, including the resolution of any disagreements between management and the external auditor regarding financial reporting;

	(iii)
	approving
fees for all audit and audit-related services and pre-approving all non-audit services to be provided to us by our
external auditor;

	(iv)
	managing
the relationship and facilitating communication between us and the external auditors; and

	(c)
	oversee
the preparation of any report that is required by any applicable securities regulatory authority to be included in the annual proxy statement,
annual information form or any other of our public disclosure documents. 

 Compensation Committee  

        Our board of directors has appointed a Compensation Committee consisting of three directors, being Eric Schneider, the Chair, Saied
Nadjafi and Paul Mountain who are "independent" under applicable Canadian securities laws. 

        The
responsibilities and mandate of the Compensation Committee are set out in a Compensation Committee Charter. The primary purposes of the Compensation Committee
are to: 

	•
	assist the board in discharging the board's oversight responsibilities relating to the compensation, development,
succession and retention of the Chief Executive Officer, President and senior management, and   

	•
	establish fair and competitive compensation and performance incentive plans. 

 Corporate Cease Trade Orders, Penalties and Bankruptcies  

        Other than as disclosed below, to our knowledge, no proposed director: 

	(i)
	is,
as at the date of this Annual Information Form, or has been, within 10 years before the date of this Annual Information Form, a director or
executive officer of any company (including our company) that, while that person was acting in that capacity,

	A.
	was
the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a
period of more than 30 consecutive days;

	B.
	was
subject to an event that resulted, after the director or executive officer ceased to be a director or executive officer, in the company being the subject
of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period of more than 30 consecutive days; or

	C.
	within
a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or
was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or 

41

 

	(ii)
	has,
within the 10 years before the date of this Annual Information Form, become bankrupt, made a proposal under any legislation relating to
bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of
the proposed director. 

Mr. Nadjafi
was a director and officer of TelcoPlus Enterprises Inc. when the British Columbia and Alberta securities commissions issued a cease trade order against the company in June,
2003. The cease trade order was issued due to the fact that the company was a shell company that had no operating business. The cease trade order was revoked in December 2003. 

Mr. Williams
was a director of Octagon Industries Inc. ("Octagon") from November 1993 to 2005. Octagon was subject to cease trade
orders issued by the British Columbia Securities Commission ("BCSC") on May 29, 2001 (revoked on August 28, 2001) and on June 24,
2004, and by the Alberta Securities Commission on June 8, 2004, for failure to file its required financial statements. Octagon was delisted from the NEX (a separate
exchange from the TSXV) for default of paying its listing fees for the third quarter of 2004. On August 12, 2001, the trustees of Octagon sent a proposal to unsecured creditors of Octagon
pursuant to the Bankruptcy and Insolvency Act (Canada). A majority of the unsecured creditors approved the proposal at a general meeting of the
creditors held on August 25, 2001. 

Mr. Williams
also served as a director of RoaDor Industries Inc. ("RoaDor"), a reporting issuer in the Provinces of British Columbia,
Alberta and Ontario, when on February 18, 2011, the BCSC and the Ontario Securities Commission each issued a cease trade order against RoaDor for failure to file its financial statements and
management's discussion and analysis related thereto for the year ended September 30, 2010. The cease trade orders remain in effect as of the date of this Annual Information Form. 

Mr. Winkley
became a director and the corporate secretary of 1608557 Ontario Inc. ("1608557") (formerly Hemosol Corp.) in
November 2008 as a part of that company's emergence from CCAA protection. In December 2008 and March 2009, the applicable Canadian securities regulatory authorities issued cease
trade orders against that company as a result of the failure to file financial statements for periods during the 2005, 2006, 2007 and 2008 fiscal years. Mr. Winkley ceased to be a director and
officer of 1608557 in December 2009. 

 Personal Bankruptcies  

        To our knowledge, none of our existing or proposed directors have, within the 10 years before the date of this Annual
Information Form, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or been subject to or instituted any proceedings, arrangements or compromise with
creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of that person. 

 Conflicts of Interest  

        Our directors are required by law to act honestly and in good faith with a view to our best interests and to disclose any interests
that they may have in any project or opportunity of SQI. If a conflict of interest arises at a meeting of the board, any director in a conflict must disclose his interest and abstain from voting on
such matter. 

        To
our knowledge, and other than disclosed herein, there are no known existing or potential conflicts of interest among SQI, our promoters, directors and officers or other members of
management of SQI or of any proposed promoter, director, officer or other member of management as a result of their outside business interests, except that certain of the directors and officers serve
as directors and officers of other companies, and therefore it is possible that a conflict may arise between their duties to SQI and their duties as a director or officer of such other companies. 

42

 
 
 

  LEGAL PROCEEDINGS AND REGULATORY ACTIONS    
    

        From time to time we are involved in various claims and legal proceedings of a nature considered normal to our business. While it is
not feasible to predict or determine the outcome of these proceedings, management believes any current actions to be without merit, and no provision in respect of these matters has been made in our
financial statements. 

 
 

  TRANSFER AGENTS AND REGISTRARS    
    

        The transfer agent and registrar for our common shares is Equity Financial Trust Company at its principal offices located in Toronto,
Ontario. 

 
 

  EXPERTS    
    

        Collins Barrow Toronto LLP, Licensed Public Accountants, are the auditors of the Company and have performed audits in respect of
the audited annual consolidated financial statements of the Company as at and for the years ended September 30, 2010 and 2009. Collins Barrow Toronto LLP, Licensed Public Accountants is
an independent auditor within the meaning of the Rules of Professional Conduct of the Institute of Chartered Accountants of Ontario. 

 
 

  ADDITIONAL INFORMATION    
    

        Additional information relating to the Company may be found on the System for Electronic Document Analysis and Retrieval which can be
accessed at www.sedar.com. Additional information, directors' and officers' remuneration and indebtedness, principal holders of common shares authorized for issuance under equity compensation plans,
if applicable, will be contained in the Company's information circular for its annual and special meeting of shareholders anticipated to be held in July 2011. Additional financial information
is also provided in the Company's financial statements and management's discussion and analysis for the year ended September 30, 2010. 

43

QuickLinks

Exhibit 4.1

FORWARD-LOOKING STATEMENTS

CORPORATE STRUCTURE

GENERAL DEVELOPMENT OF THE BUSINESS

DESCRIPTION OF THE BUSINESS

DIVIDENDS AND DISTRIBUTIONS

DESCRIPTION OF CAPITAL STRUCTURE

MARKET FOR SECURITIES

DIRECTORS AND OFFICERS

LEGAL PROCEEDINGS AND REGULATORY ACTIONS

TRANSFER AGENTS AND REGISTRARS

EXPERTS

ADDITIONAL INFORMATIONQuickLinks
 -- Click here to rapidly navigate through this document

 
 

  Exhibit 4.2    
    

          SQI DIAGNOSTICS INC.  

NOTICE OF ANNUAL AND SPECIAL MEETING OF

SHAREHOLDERS  

 TO BE HELD ON JULY 7, 2011  

 – AND – 

 MANAGEMENT PROXY CIRCULAR  

 

 SQI DIAGNOSTICS INC.

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

TO BE HELD ON JULY 7, 2011  

        NOTICE IS HEREBY GIVEN that the annual and special meeting of the shareholders
(the "Meeting") of SQI Diagnostics Inc.
(the "Company") will be held at the offices of McCarthy Tétrault LLP, located at 66 Wellington Street West,
Suite 5300, Toronto, Ontario, on Thursday, July 7, 2011, at 11:00 a.m. (Toronto time) for the following purposes: 

	1.
	To
receive the audited financial statements of the Company for the year ended September 30, 2010 together with the report of the auditors thereon;

	2.
	To
elect directors of the Company for the ensuing year;

	3.
	To
re-appoint Collins Barrow LLP as auditors of the Company for the current year and to authorize the directors to fix the remuneration of
the auditors;

	4.
	To
pass an ordinary resolution to make certain amendments to the Company's stock option plan, including to provide that the maximum number of common shares
issuable under the plan be set at a maximum of 10% of the issued and outstanding common shares of the Company; and

	5.
	To
transact such other business as may properly come before the Meeting or any adjournment thereof. 

        This
notice is accompanied by a form of proxy and a management proxy circular dated June 8, 2011 (the "Information
Circular"). 

        The
board of directors of the Company has fixed the close of business on June 6, 2011, as the record date for the determination of holders of common shares entitled to notice of
the Meeting and any adjournments thereof. 

        It
is desirable that as many shares as possible be represented at the Meeting. If you do not expect to attend, and would like your shares represented, please read the enclosed
Information Circular and complete the enclosed instrument of proxy and return it as soon as possible. To be effective, the proxy must be deposited  

	•
	in person at the office of the Company's registrar and transfer agent,
Equity Financial Trust Company, at 200 University Ave, Suite 400, Toronto, Ontario, M5H 4H1;   

	•
	by fax to 416-595-9593, attention: Proxy
Department; or   

	•
	online at www.voteproxyonline.com 

        by
not later than 11:00 a.m. (Toronto time) on July 5, 2011 or, if the Meeting is adjourned, not later than 48 hours, excluding Saturdays, Sundays and holidays,
prior to the time of such adjourned Meeting, unless the Chairman of the Meeting elects to exercise his discretion to accept proxies received subsequently. 

        As
there is a labour disruption currently affecting postal service in Canada, PLEASE DO NOT ATTEMPT TO MAIL YOUR PROXY. 

        The
accompanying Information Circular provides additional information relating to the matters to be dealt with at the Meeting. 

DATED
at Toronto, Ontario, this 8th day of June, 2011. 

BY
ORDER OF THE BOARD OF DIRECTORS 

/s/
"Claude Ricks"

Claude
Ricks

President and Chief Executive Officer 

1

 

 SQI DIAGNOSTICS INC.

ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

INFORMATION CIRCULAR  

The
information presented in this management proxy circular (the "Information Circular") is dated as at June 8, 2011, unless otherwise
indicated. 

I.     GENERAL PROXY INFORMATION  

 SOLICITATION OF PROXIES  

        This Information Circular is furnished in connection with the solicitation by and on behalf of the management of the Company of proxies
to be used at the annual and special meeting of the Company (the "Meeting") to be held at the offices of McCarthy
Tétrault LLP, located at 66 Wellington Street West, Suite 5300, Toronto, Ontario, on Thursday, July 7, 2011, at 11:00 a.m. (Toronto time) for the
purposes set forth in the accompanying notice of annual and special meeting of Shareholders ("Notice of Meeting"), and at any adjournment or
adjournments thereof. In addition to solicitation by mail, certain officers, directors, employees and service providers of the Company may solicit proxies by telephone, electronic mail, telecopier or
personally. These persons will receive no compensation for such solicitation other than their regular fees or salaries. The head office of the Company is located at 36 Meteor Drive, Toronto,
Ontario, M9W 1A4. 

        No
person is authorized to give any information or to make any representation not contained in this Information Circular, and if given or made, such information or representation should
not be relied upon as having been authorized. This Information Circular does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities, or the solicitation of a proxy,
by any person in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to any person to whom
it is unlawful to make such an offer or solicitation of any offer or proxy solicitation. Neither delivery of this Information Circular nor any distribution of the securities referred to in this
Information Circular shall, under any circumstances, create an implication that there has been no change in the information set forth herein since the date of this Information Circular. 

        The
Canada Business Corporations Act (the "CBCA") the Company's governing statute,
provides that shareholder proposals must be received by March 9, 2012, to be considered for inclusion in the management proxy circular and the form of proxy for the 2012 annual meeting of
shareholders of the Company ("Shareholders"). 

 APPOINTMENT OF PROXYHOLDER  

        The persons named in the enclosed form of proxy are officers or directors of the Company
(the "Management Proxyholders"). 

        A SHAREHOLDER DESIRING TO APPOINT SOME OTHER PERSON, WHO NEED NOT BE A SHAREHOLDER OF THE COMPANY, TO REPRESENT THEM AT THE MEETING MAY DO
SO by inserting such other person's name in the blank space provided in the form of proxy and depositing the completed proxy with the Company's registrar and transfer agent,
Equity Financial Trust Company, as instructed below. A proxy can be executed by the Shareholder or his attorney duly authorized in writing, or, if the Shareholder is a corporation, under its corporate
seal by an officer or attorney duly authorized. 

        In
addition to any other manner permitted by law, a proxy may be revoked before it is exercised by instrument in writing executed and delivered in person or by fax, as described below,
any time up to and including the last business day preceding the day of the Meeting or any adjournment at which the proxy is to be used or delivered to the Chair of the Meeting on the day of the
Meeting or any adjournment prior to the time of voting and upon either such occurrence, the proxy is revoked. 

2

 

 VOTING BY PROXY  

        Shares represented by a properly executed proxy will be voted or be withheld from voting on each matter referred to in the Notice of
Meeting in accordance with the instructions of the Shareholder on any ballot that may be called for and if the Shareholder specifies a choice with respect to any matter to be acted upon, the shares
will be voted accordingly. 

        If a Shareholder does not specify a choice and the Shareholder has appointed one of the Management Proxyholders as proxyholder, the Management Proxyholder will
vote in favour of the matters specified in the Notice of Meeting and in favour of all other matters proposed by management at the Meeting.

        The enclosed form of proxy also gives discretionary authority to the person named therein as proxyholder with respect to amendments or variations to matters
identified in the Notice of Meeting and with respect to other matters which may properly come before the Meeting. At the date of this Information Circular, management of the
Company knows of no such amendments, variations or other matters to come before the Meeting. 

 DEPOSIT OF PROXY  

        Proxies must be deposited: 

	•
	in person at the office of the Company's registrar and transfer agent,
Equity Financial Trust Company, at 200 University Ave, Suite 400, Toronto, Ontario, M5H 4H1;   

	•
	by fax to 416-595-9593, attention: Proxy
Department; or   

	•
	online at www.voteproxyonline.com 

by
not later than 11:00 a.m. (Toronto time) on July 5, 2011 or, if the Meeting is adjourned, not later than 48 hours, excluding Saturdays, Sundays and holidays, prior to the time
of such adjourned Meeting, unless the Chairman of the Meeting elects to exercise his discretion to accept proxies received subsequently. 

        As
there is a labour disruption currently affecting postal service in Canada, PLEASE DO NOT ATTEMPT TO MAIL YOUR PROXY. 

 DISTRIBUTION TO NOBOS  

        In accordance with the requirements of the Canadian Securities Administrators and National Instrument 54-101,
"Communication with Beneficial Owners of Securities of a Reporting Issuer" ("NI-54-101"), the Company will have distributed
copies of the Notice of Meeting, this Information Circular and the form of proxy (collectively, the "Meeting Materials") directly to persons
beneficially holding (each a "Non-Registered Holder") common shares of the Company ("Common
Shares") who have provided instructions to an intermediary (an "Intermediary") that such Non-Registered
Holder does not object to the Intermediary disclosing ownership information about the Non-Registered Holder ("Non-Objecting Beneficial
Owner" or "NOBO"). 

        These securityholder materials are being sent to both registered and non-registered owners of the securities. If you are a non-registered
owner, and the Company or its agent has sent these materials directly to you, your name and address and information about your holdings of securities have been obtained in accordance with applicable
securities regulatory requirements from the intermediary holding on your behalf.

        By choosing to send these materials to you directly, the Company (and not the intermediary holding on your behalf) has assumed responsibility for
(i) delivering these materials to you, and (ii) executing your proper voting instructions. Please return your voting instructions as specified in the request for proxy enclosed with
mailings to NOBOs.

        The
meeting materials distributed by the Company's agent to NOBOs include a proxy. Please carefully review the instructions on the proxy for completion and deposit. 

3

 

 DISTRIBUTION TO OBOS  

        In addition, the Company will cause its agent to deliver copies of the meeting materials to the clearing agencies and Intermediaries
for onward distribution to those Non-Registered Shareholders who have provided instructions to an Intermediary that the Non-Registered Holder objects to the Intermediary
disclosing ownership information about the Non-Registered Holder ("Objecting Beneficial Owner"
or "OBO"). 

        Intermediaries
are required to forward the meeting materials to OBOs unless an OBO has waived his or her right to receive them. Intermediaries often use service companies such as
Broadridge to forward the meeting materials to OBOs. Generally, those OBOs who have not waived the right to receive meeting materials will either: 

	(i)
	be
given a form of proxy which has already been signed by the intermediary (typically by a facsimile stamped signature), which is restricted as to the
number of shares beneficially owned by the OBO, but which is otherwise uncompleted. This form of proxy need not be signed by the OBO. In this case, the OBO who wishes to submit a proxy should properly
complete the form of proxy and deposit it with Equity Financial Trust Company in the manner set out above in this Information Circular with respect to the Common Shares beneficially owned by such
OBO; OR

	(ii)
	more
typically, be given a voting registration form which is not signed by the Intermediary and which, when properly completed and signed by the OBO and
returned to the Intermediary or its service company, will constitute authority and instructions (often called a "Voting Instruction Form") which the
Intermediary must follow. Typically, the Voting Instruction Form will consist of a one page pre-printed form. The purpose of this procedure is to permit the OBO to direct the voting of the
shares he or she beneficially owns. 

        Should a Non-Registered Holder who receives one of the above forms wish to vote at the Meeting in person, the Non-Registered Holder should
strike out the names of the persons
named in the form and insert the Non-Registered Holder or such other person's name in the blank space provided. In either case, Non-Registered Holders should carefully follow
the instructions, including those regarding when and where the proxy or Voting Instruction Form is to be delivered.

        An
OBO may revoke a Voting Instruction Form or a waiver of the right to receive meeting materials and to vote which has been given to an Intermediary at any time by written notice to the
Intermediary, except that an Intermediary is not required to act on a revocation of a Voting Instruction Form or of a waiver of the right to receive meeting materials and to vote which is not received
by the Intermediary at least seven days prior to the Meeting. Any OBO wishing to deliver such a revocation should be mindful of the current labour disruption affecting postal service in Canada and
choose an appropriate method of delivery given such disruption. 

 REVOCABILITY OF PROXY  

        Any registered Shareholder or NOBO who has returned a proxy may revoke it at any time before it has been exercised. In addition to
revocation in any other manner permitted by law, a registered Shareholder or NOBO, his or her attorney authorized in writing or, if the registered Shareholder or NOBO is a corporation, a corporation
under its corporate seal or by an officer or attorney thereof duly authorized, may revoke a proxy by instrument in writing, including a proxy bearing a later date. The instrument revoking the proxy
must be deposited in person or by fax at the registered office of the Company, at any time up to and
including the last business day preceding the date of the Meeting, or any adjournment thereof, or with the Chairman of the Meeting on the day of the Meeting. As there is a labour disruption currently
affecting postal service in Canada, PLEASE DO NOT ATTEMPT TO MAIL YOUR REVOCATION OF PROXY. Only registered Shareholders or NOBOs have the right to
revoke a proxy. OBOs who wish to change their vote must, at least 7 days before the Meeting, arrange for their nominees to revoke the proxy on their behalf. 

 VOTING SHARES AND PRINCIPAL HOLDERS THEREOF  

        The authorized capital of the Company consists of an unlimited number of Common Shares. As of the date of this Information Circular,
33,946,258 Common Shares are issued and outstanding as fully paid and non-assessable. 

4

 

        Each
Shareholder is entitled to one vote for each Common Share shown as registered in his or her name on the list of Shareholders, which will be available for inspection at the Meeting.
The board of directors of the Company (the "Board") have fixed June 6, 2011, as the record date for the Meeting. Shareholders of record as
at that date are entitled to receive notice of the Meeting. Shareholders of record will be entitled to vote those Common Shares of the Company included in the list of Shareholders entitled to vote at
the Meeting prepared as at the record date. 

        To
the knowledge of the directors and senior officers of the Company, no person beneficially owns, directly or indirectly, or exercises control or direction over, more than 10% of the
issued and outstanding Common Shares of the Company. 

II.    PARTICULARS OF MATTERS TO BE ACTED UPON  

1.     Financial Statements and Auditor's Report  

        The annual report of the Company for the fiscal year ended September 30, 2010, including the financial statements for the fiscal year ended
September 30, 2010, together with the report of the auditors thereon will be submitted at the Meeting. Receipt at such Meeting of the auditors' report and the Company's financial statements for
its last completed fiscal year will not constitute approval or disapproval of any matters referred to therein. 

        Under
NI 54-101, a person or company who wishes to receive interim financial statements from the Company must deliver a written request for such material to the
Company, together with a signed statement that the person or company is the owner of securities (other than debt instruments) of the Company. Shareholders who wish to receive interim financial
statements are encouraged to send the enclosed return card, together with the completed form of proxy, in the addressed envelope provided, to the Company's registrar and transfer agent, Equity
Financial Trust Company, at 200 University Ave, Suite 400, Toronto, Ontario, M5H 4H1. The Company will maintain a supplemental mailing list of persons and companies wishing to
receive interim financial statements. Additional information relating to the Company is on SEDAR at www.sedar.com. Shareholders may contact the Company at 36 Meteor Drive, Toronto, Ontario
M9W 1A4 to request copies of the Company's financial statements and management discussion and analysis ("MD&A"). 

        Financial
information is provided in the Company's comparative financial statements and MD&A for its most recently completed financial year, which are filed on SEDAR. 

2.     Election of Directors  

        The directors of the Company are elected at each annual meeting and hold office until the next annual meeting or until their successors are appointed. In the
absence of instructions to the contrary, the enclosed proxy will be voted for the nominees herein listed. 

        Management
of the Company proposes to nominate each of the following persons for election as a director. Each director elected at the Meeting will hold office until the next annual
meeting of Shareholders or until his or her successor is elected or appointed, unless his or her office is earlier vacated according to the provisions of the 

5

 

by-laws
of the Company and the CBCA. Information concerning such persons, as furnished by the individual nominees, is as follows: 

 

 

										
	Name, Place of

Residence and

Director Since

 
	 	Principal Occupation

 
	 	Number of Common

Shares Beneficially

Owned or Controlled 	 	Percentage of

Common Shares 	 
	Claude Ricks

Barrie, ON

May, 2007	 	Currently and since May 2007, Mr. Ricks has been the President, Chief Executive Officer and a director of SQI Diagnostics Inc. Prior to that, Mr. Ricks was the Chief Executive Officer of SQI
Diagnostics Systems Inc., a wholly-owned subsidiary of the Company.	 	 	1,992,157	 	 	6%	 
	
Dr. Peter Lea

Toronto, ON

May, 2007	
 	
Currently and since May 2007, Dr. Lea has been the Chief Science Officer and a director of SQI Diagnostics Inc.. Prior to that, Dr. Lea was Chief Science Officer and director of SQI Diagnostics
Systems Inc a wholly-owned subsidiary of the Company.	
 	
 	
2,173,904	
 	
 	
6%	
 
	
Eric Schneider (1) (2)

Waterloo, ON

May, 2007	
 	
Currently and for the past five years, Mr. Schneider is a partner in the law firm Miller Thomson LLP and its predecessors.	
 	
 	
380,635	
 	
 	
1%	
 
	
Saied Nadjafi (2)

Toronto, ON

May, 2007	
 	
Currently and for the past five years Mr. Nadjafi is an independent business man.	
 	
 	
1,931,475	
 	
 	
6%	
 
	
David Williams (1)

Toronto, ON

May, 2007	
 	
Currently and for the past five years, Mr. Williams is the President of Roxborough Holdings Limited, a Toronto based investment company.	
 	
 	
477,225	
 	
 	
1%	
 
	
Paul J. Mountain (2)

Welland, ON

August, 2007	
 	
Currently and since August 2007, Mr. Mountain has been an independent consultant. Prior to that and since January 1990 Mr. Mountain was Vice President of Science and Technology at MDS Inc., a
Toronto-based diversified healthcare company.	
 	
 	
Nil	
 	
 	
—	
 
	
Peter Winkley (1)

Mississauga, ON

November, 2007	
 	
Currently and since September 2010, Mr. Winkley is the Vice President and Chief Financial Officer of Algoma Capital Corporation. Prior to that, Mr. Winkley was the Chief Financial Officer of Therapure
Biopharma Inc. a Mississauga-based biologics contract manufacturer. Prior to this, Mr. Winkley was Vice-President, Corporate Finance at MDS Inc.	
 	
 	
Nil	
 	
 	
—

	
 

 

 

	(1)
	Member
of the audit committee (the "Audit Committee") (appointed annually).

	(2)
	Member
of the compensation committee (the "Compensation Committee") (appointed annually). 

 

         No proposed director is to be elected under any arrangement or understanding between the proposed director and any other person or company, except
the directors and executive officers of the company acting solely in such capacity. 

6

 

 Corporate Cease Trade Orders, Penalties and Bankruptcies  

        Other than as disclosed below, to the knowledge of the Company, no proposed director: 

	(a)
	is,
as at the date of the Information Circular, or has been, within 10 years before the date of the Information Circular, a director or executive
officer of any company (including the Company) that, while that person was acting in that capacity,

	(i)
	was
the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a
period of more than 30 consecutive days;

	(ii)
	was
subject to an event that resulted, after the director or executive officer ceased to be a director or executive officer, in the company being the
subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period of more than 30 consecutive
days; or

	(iii)
	within
a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency
or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or

	(b)
	has,
within the 10 years before the date of the Information Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy
or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed
director. 

        Mr. Nadjafi
was a director and officer of TelcoPlus Enterprises Inc. when the British Columbia and Alberta securities commissions issued a cease trade order against the
company in June, 2003. The cease trade order was issued due to the fact that the company was a shell company that had no operating business. The cease trade order was revoked in December 2003. 

        Mr. Williams
was a director of Octagon Industries Inc. ("Octagon") from November 1993 to 2005. Octagon was subject to
cease trade orders issued by the British Columbia Securities Commission ("BCSC") on May 29, 2001 (revoked on August 28, 2001) and on
June 24, 2004, and by the Alberta Securities Commission on June 8, 2004, for failure to file its required financial statements. Octagon was delisted from the NEX (a separate
exchange from the TSX Venture Exchange (the "TSXV")) for default of paying its listing fees for the third quarter of 2004. On August 12,
2001, the trustees of Octagon sent a proposal to unsecured creditors of Octagon pursuant to the Bankruptcy and Insolvency Act (Canada). A majority of
the unsecured creditors approved the proposal at a general meeting of the creditors held on August 25, 2001. 

        Mr. Williams
also served as a director of RoaDor Industries Inc. ("RoaDor"), a reporting issuer in the Provinces of British
Columbia, Alberta and Ontario, when on February 18, 2011, the BCSC and the Ontario Securities Commission each issued a cease trade order against RoaDor for failure to file its financial
statements and management's discussion and analysis related thereto for the year ended September 30, 2010. The cease trade orders remain in effect as of the date of this Information Circular. 

        Mr. Winkley
became a director and the corporate secretary of 1608557 Ontario Inc. ("1608557") (formerly Hemosol
Corp.) in November 2008 as a part of that company's emergence from CCAA protection. In December 2008 and March 2009, the applicable Canadian securities regulatory authorities
issued cease trade orders against that company as a result of the failure to file financial statements for periods during the 2005, 2006, 2007 and 2008 fiscal years. Mr. Winkley ceased to be a
director and officer of 1608557 in December 2009. 

 Personal Bankruptcies  

        To the Company's knowledge, no existing or proposed director of the Company has, within the 10 years before the date of this
Information Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or been subject to or instituted any proceedings, arrangements or compromise with
creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of that person. 

7

 

 Conflicts of Interest  

        The directors are required by law to act honestly and in good faith with a view to the best interests of the Company and to disclose
any interests that they may have in any project or opportunity of the Company. If a conflict of interest arises at a meeting of the Board, any director in a conflict will disclose his interest and
abstain from voting on such matter. 

        To
the Company's knowledge, and other than disclosed herein, there are no known existing or potential conflicts of interest among the Company, its promoters, directors and officers or
other members of management of the Company or of any proposed promoter, director, officer or other member of management as a result of their outside business interests, except that certain of the
directors and officers serve as directors and officers of other companies, and therefore it is possible that a conflict may arise between their duties to the Company and their duties as a director or
officer of such other companies. 

        Management recommends that Shareholders vote FOR the election of the directors.

3.     Re-Appointment of Auditor  

        The auditor of the Company is Collins Barrow LLP and has been since 2005. Unless otherwise instructed, the proxies given pursuant to this solicitation will
be voted for the re-appointment of Collins Barrow LLP as the auditors of the Company to hold office for the ensuing year at a remuneration to be fixed by the directors. 

        Management recommends that Shareholders vote FOR the election of the auditors and for the Board to fix the remuneration of the auditors.  

 4.     Amendment of Stock Option Plan  

        On March 27, 2007, Shareholders approved the Company's stock option plan (the "Stock Option Plan")
which reserves for issuance a fixed number of Common Shares pursuant to the terms and conditions of such plan. On June 8, 2011, the Board approved certain amendments to the Stock Option
Plan to: 

	•
	clarify the Company's obligations with respect to withholding tax;   

	•
	provide for the extension of the length of a stock option term in the event that the Company is in a period during which
designated directors, officers and employees of the Company cannot trade Common Shares pursuant to the Company's policy respecting restrictions on directors', officers' and employee trading which is
in effect at that time;   

	•
	provide for certain tax and other legal requirements for issuances of options to employees resident in the
United States; and   

	•
	to amend the Stock Option Plan to provide that the maximum number of Common Shares which may be reserved and set aside for
issue under the Stock Option Plan will be set at a maximum of 10% of the issued and outstanding Common Shares at the time of the option grant (on a non-diluted basis), such that the
Stock Option Plan will become a "rolling" stock option plan pursuant to the policies of the TSXV. 

        A
copy of the proposed Stock Option Plan is on our website at www.sqidiagnostics.com. The contents of this website are not incorporated by reference into this Information Circular. 

        As
a result of the "rolling cap" described in (iv) above, the Stock Option Plan must be approved by shareholders on an annual basis. At the Meeting, Shareholders will be asked to
approve the following ordinary resolution of Shareholders approving the amendment to the Stock Option Plan providing for a rolling maximum number of Common Shares issuable under such plan
(the "Stock Option Plan Resolution"): 

BE
IT RESOLVED THAT: 

	1.
	The
amendments to the stock option plan (the "Stock Option Plan") of the Company described in the
Company's management proxy circular for this annual and special meeting of shareholders be authorized and approved; and 

8

 

	2.
	Any
one director or officer of the Company be and is hereby authorized, for and on behalf of the Company, to execute and deliver any and all documents and
instruments and to do all other things as in the opinion of such director or officer may be necessary or desirable to implement this resolution and the matters authorized hereby, such determination to
be conclusively evidenced by the execution and delivery of any such document or instrument, and the taking of any such action and the directors are hereby authorized to grant from time to time options
in accordance with the provisions of the Stock Option Plan and the policies of the TSX Venture Exchange. 

        The
persons named in the accompanying form of proxy will, in the case of a ballot and in the absence of specifications or instructions to vote against the Stock Option Plan Resolution on
the form of proxy, vote for the approval of the Stock Option Plan Resolution. 

        In order to be effective, the Stock Option Plan Resolution must be approved by holders of a majority of the shares represented in person or by proxy at
the Meeting.

        Management recommends that Shareholders vote FOR the Stock Option Plan Resolution.

III.  EXECUTIVE COMPENSATION  

        The following table (presented in accordance with National Instrument Form 51-102F6
("Form 51-102F6") ("Statement of Executive Compensation") sets forth all annual and
long term compensation for services in all capacities to the Company for the three most recently completed financial years (to the extent required by Form 51-102F6) in
respect of the Chief Executive Officer and the Chief Financial Officer as at September 30, 2010, and the other three most highly compensated executive officers of the Company as at
September 30, 2010, whose individual total salary and bonus for the most recently completed financial year exceeded $150,000 and any individual who would have satisfied these criteria but for
the fact that individual was not serving as such an officer at the end of the most recently completed financial year. All figures are presented in Canadian dollars. 

 Summary Compensation Table  

 

 

																				
	 
	 	 
	 	 
	 	 
	 	 
	 	Long Term Compensation 	 	 

	 
	 	 
	 	 
	 	 
	 	 
	 	Awards 	 	 
	 	 

	 
	 	 
	 	Annual Compensation 	 	Securities

Under

Option/

SARs

Granted

(#) 	 	 
	 	 
	 	 

	 
	 	 
	 	Shares/Units

Subject to

Resale

Restrictions

($) 	 	Payouts 	 	 

	 
	 	 
	 	 
	 	 
	 	Other

Annual

Compensation

($) 	 	 

	NEO

Name and

Principal Position

 
	 	Year 	 	Salary

($) 	 	Bonus

($) 	 	LTIP

Payouts

($) 	 	All Other

Compensation

($) 
	 Claude Ricks(1)

President and Chief Executive Officer
	 	 	2010

2009	 	 	182,308

171,923	 	 	12,308

Nil	 	Nil

Nil	 	Nil

Nil	 	Nil

Nil	 	Nil

Nil	 	Nil

Nil
	 Andrew Morris(2)

Chief Financial Officer
	 	 	

2010

2009	 	 	

166,731

160,961	 	 	

9,231

22,500	 	 Nil

Nil
	 	 Nil

Nil
	 	 Nil

Nil
	 	 Nil

Nil
	 	 Nil

Nil

	 Dr. Peter Lea(3)

Chief Science Officer
	 	 	

2010

2009	 	 	

151,154

150,000	 	 	

6,154

Nil	 	 Nil

Nil
	 	 Nil

Nil
	 	 Nil

Nil
	 	 Nil

Nil
	 	 Nil

Nil

 

 

	(1)
	Mr. Ricks
was appointed Chief Executive Officer of the Company in April, 2007. Prior to that, Mr. Ricks was the Chief Executive Officer of SQI
Diagnostics Systems Inc., the wholly-owned subsidiary of the Company.

	(2)
	Mr. Morris
was appointed Chief Financial Officer of the Company in April, 2007. Prior to that, Mr. Morris was the Chief Financial Officer of
SQI Diagnostics Systems Inc., the wholly-owned subsidiary of the Company.

	(3)
	Mr. Lea
was appointed Chief Science Officer of the Company in April, 2007. Prior to that, Mr. Lea was the Chief Science Officer of SQI
Diagnostics Systems Inc., the wholly-owned subsidiary of the Company. 

 

 9

 
 

 

  Compensation Discussion & Analysis  

 Composition of the Compensation Committee  

        In August 2007, the Company formed the compensation committee (the "Compensation
Committee") to meet as required and review senior management compensation and the overall compensation policies and practices of the Company. Prior to the formation of the
Compensation Committee, the Board as a whole performed these functions. The members of the Compensation Committee are Messrs. Mountain, Schneider and Nadjafi, all of whom are independent
directors. 

 Compensation Philosophy  

        For compensation matters, the Compensation Committee of the Board is responsible for: 

	•
	reviewing and approving the compensation of the executive officers of the Company;   

	•
	recommending to the Board other executive compensation, incentive-based plans and equity-based plans;  

	•
	evaluating and recommending compensation of the director's of the Company and succession planning; and  

	•
	reviewing compensation disclosure in public documents. 

        The
Compensation Committee considers the following objectives when reviewing compensation: 

	•
	retaining individuals critical to the success of the Company;   

	•
	rewarding performance of individuals by recognizing their contribution to the Company; and  

	•
	compensating individuals based on their performance and, to the extent applicable, on similar compensation for companies
at a comparable state of development. 

        To
encourage ownership interest in the Company and to focus on the long-term performance of the Company over a period of time, the Company has adopted, as a
long-term incentive, the Stock Option Plan that enables officers, directors and key employees to acquire Common Shares pursuant to the terms and conditions of the Stock Option Plan. 

 Compensation Procedures  

        In 2010, the Compensation Committee reviewed the compensation for the senior executive officers. Senior management was responsible for
the review of compensation for other officers and key employees. Such review was based on performance. The compensation for senior executive officers, following compensation committee review was
effected by this review bringing compensation to the levels reflected in the current employment agreements with the Named Executive Officers. 

 Chief Executive Officer's Compensation  

        Mr. Ricks received a base salary of $182,308. The compensation of the Company's Chief Executive Officer is based on the same
criteria as that used in determining the compensation payable to the Company's other executive officers. In determining the salary paid to Mr. Ricks during the past fiscal year, the
Compensation Committee took into account salary, short-term incentive levels and long-term incentive levels of comparable companies, as well as the historical salaries of
management of the Company. 

        Submitted
by the Compensation Committee: 

        Eric
Schneider, Saied Nadjafi, and Paul Mountain 

10

 

 Outstanding Option-Based Awards  

        The Company had the following option-based awards outstanding for Named Executive Officers at September 30, 2010. 

 

 

													
	Name

 
	 	Number of Securities

Underlying Unexercised

Options (#) 	 	Option

Exercise

Price

($) 	 	Option

Expiration

Date 	 	Value of Unexercised

in-the-Money Options(1)

($) 	 
	 Claude Ricks
	 	 	150,000	 	 	1.60	 	February 26, 2013	 	 	198,000	 
	 Andrew Morris
	 	 	250,000	 	 	1.60	 	February 26, 2013	 	 	330,000	 
	 Peter Lea
	 	 	150,000	 	 	1.60	 	February 26, 2013	 	 	198,000	 

 

 

	(i)
	Closing
market value on September 30, 2010 was $2.92. 

 

  Incentive Plan Awards — Value Vested or Earned During Year Ended September 30, 2010  

        The following incentive plan awards for Named Executive Officers vested during the year ended September 30, 2010. 

 

 

					
	Name

 
	 	Option-Based Awards — Value Vested

During the Year ended

September 30,

2010(1) 	 
	 Claude Ricks
	 	 	$66,000	 
	 Andrew Morris
	 	 	$49,500	 
	 Peter Lea
	 	 	$66,000	 

 

 

	(1)
	Closing
market value on September 30, 2010 was $2.92. 

 

  Securities Authorized for Issuance under Equity Compensation Plans  

        The following table gives certain information as of September 30, 2010, being the Company's most recently completed financial
year, with respect to the Stock Option Plan under which equity securities of the Company are authorized for issuance. 

 

 

											
	Plan Category

 
	 	Number of securities to be issued upon exercise of

outstanding options,

warrants and rights 	 	Weighted-average

exercise price of

outstanding options 	 	Number of securities remaining available for future issuance under equity

compensation plans 	 
	 Equity compensation plans approved by security holders
	 	 	1,764,000	 	 	$1.75	 	 	291,367	 

 

  Termination and Change of Control Benefits  

Claude Ricks — President and Chief Executive Officer 

        The
Company has an employment agreement with Claude Ricks, the President and Chief Executive Officer of the Company made as of January 1, 2008 for an
initial term of two years which was renewed for an additional two year term. The agreement provides, among other things, that: 

	(a)
	Upon
the termination by the Company of Claude Ricks' employment other than as a result of the death or disability of Mr. Ricks or just cause or upon
the termination by Mr. Ricks for good reason, the Company shall thereupon pay to him, in no more than two lump sum payments, an amount equal to the lesser of: (i) one times the then
current annual salary plus any bonus amounts, and (ii) an amount equal to the result obtained when the then current annual salary is multiplied by a fraction, the 

11

 

numerator
of which is the number of days between the date of termination and Mr. Ricks' retirement date and the denominator of which is 365; and  

	(b)
	If
Mr. Ricks' employment is terminated as a result of a change of control, the Company shall pay to him no more than two lump sum payment, the amount
of which is equal to the lesser of: (i) twice the then current annual salary; and (ii) an amount equal to the result obtained when the then current annual salary is multiplied by a
fraction, the numerator of which is the number of days between the termination and Mr. Ricks' retirement date and the denominator of which is 365. 

Andrew Morris — Chief Financial Officer 

        The
Company has an employment agreement with Andrew Morris, the Chief Financial Officer of the Company made as of January 1, 2008 for an initial term of
two years which was renewed for an additional two year term. The agreement provides, among other things, that: 

	(a)
	Upon
the termination by the Company of Mr. Morris' employment other than as a result of the death or disability of Mr. Morris or just cause or
upon the termination by Mr. Morris for good reason, the Company shall thereupon pay to him, in no more than two lump sum payments, an amount equal to the lesser of: (i) one times the
then current annual salary plus any bonus amounts, and (ii) an amount equal to the result obtained when the then current annual salary is multiplied by a fraction, the numerator of which is the
number of days between the date of termination and Mr. Morris' retirement date and the denominator of which is 365; and

	(b)
	If
Mr. Morris' employment is terminated as a result of a change of control, the Company shall pay to him no more than two lump sum payment, the
amount of which is equal to the lesser of: (i) twice the then current annual salary; and (ii) an amount equal to the result obtained when the then current annual salary is multiplied by
a fraction, the numerator of which is the number of days between the termination and Mr. Morris' retirement date and the denominator of which is 365. 

Dr. Peter Lea — Chief Science Officer 

        The
Company has an employment agreement with Dr. Peter Lea, the Chief Science Officer of the Company made as of January 1, 2008 for an initial
term of two years which was renewed for an additional two year term. The agreement provides, among other things, that: 

	(a)
	Upon
the termination by the Company of Dr. Lea's employment other than as a result of the death or disability of Dr. Lea or just cause or upon
the termination by Dr. Lea for good reason, the Company shall thereupon pay to him, in no more than two lump sum payments, an amount equal to the lesser of: (i) one times the then
current annual salary plus any bonus amounts, and (ii) an amount equal to the result obtained when the then current annual salary is multiplied by a fraction, the numerator of which is the
number of days between the date of termination and Dr. Lea's retirement date and the denominator of which is 365; and

	(b)
	If
Dr. Lea's employment is terminated as a result of a change of control, the Company shall pay to him no more than two lump sum payment, the amount
of which is equal to the lesser of: (i) twice the then current annual salary; and (ii) an amount equal to the result obtained when the then current annual salary is multiplied by a
fraction, the numerator of which is the number of days between the termination and Dr. Lea's retirement date and the denominator of which is 365. 

 Compensation of Directors  

        Non-management directors were paid an annual retainer of $15,000. Peter Winkley, the Chair of the Audit Committee was paid
an additional annual retainer of $5,000. Paul Mountain was appointed chair of an ad hoc

12

 

committee
of the Board effective September 1, 2010 and is paid an additional $5,000 annually. Total amounts paid to each non-management director are set out below. 

 

 

					
	Director Name

 
	 	Compensation Paid

During the Fiscal Year-Ending

September 30, 2010

($) 	 
	 Paul Mountain
	 	 	15,417	 
	 Eric Schneider
	 	 	15,000	 
	 David Williams
	 	 	15,000	 
	 Saied Nadjafi
	 	 	15,000	 
	 Peter Winkley
	 	 	20,000	 

 

         Directors
were eligible to participate in the Company's Stock Option Plan during the financial year ended September 30, 2010. The following options were granted to directors in
fiscal 2010. 

 

 

														
	Name

 
	 	Number of Securities

Underlying

Unexercised Options

(#) 	 	Option Exercise

Price

($) 	 	Option

Grant Date 	 	Expiry Date 	 
	 David Williams
	 	 	35,000	 	$	2.50	 	 	August 16, 2010	 	 	August 16, 2010	 
	 Eric Schneider
	 	 	35,000	 	$	2.50	 	 	August 16, 2010	 	 	August 16, 2010	 
	 Paul Mountain
	 	 	35,000	 	$	2.50	 	 	August 16, 2010	 	 	August 16, 2010	 
	 Peter Winkley
	 	 	35,000	 	$	2.50	 	 	August 16, 2010	 	 	August 16, 2010	 
	 Saied Nadjafi
	 	 	35,000	 	$	2.50	 	 	August 16, 2010	 	 	August 16, 2010	 

 

  Indebtedness of Directors and Officers  

        Except as disclosed below, there is no indebtedness of any director, executive officer, proposed nominee for election as a director or
associate of them, to or guaranteed or supported by the Company either pursuant to an employee stock purchase program of the Company or otherwise, during the most recently completed
financial year.  

	(a)
	In
May, 2005, SQI Diagnostics Systems Inc. loaned $10,000 to Andrew Morris in order for Mr. Morris to exercise 100,000 warrants at an
exercise price of $0.10 per share. As at the date of this Information Circular, the loan has been paid in full.

	(b)
	In
November 2004, SQI Diagnostics Systems Inc. loaned $97,000 to Peter Lea. As at the date of this Information Circular, the loan has been
paid in full. 

IV.    INTEREST OF INSIDERS IN MATTERS TO BE ACTED UPON  

        Except as set out elsewhere in this Information Circular, no person who has been a director or executive officer of the Company at any time since the beginning of
the Company's last financial year, no proposed nominee of management of the Company for election as a director of the Company and no associate or affiliate of the foregoing persons, has any material
interest, direct or indirect, by way of beneficial ownership or otherwise, in matters to be acted upon at the Meeting other than the election of directors or the appointment of auditors. 

        To
the knowledge of the Company, no informed person or proposed director of the Company and no associate or affiliate of the foregoing persons has or has had any material interest,
direct or indirect, in any transaction since the commencement of the Company's most recently completed financial year or in any proposed transaction which in either such case has materially affected
or would materially affect the Company. 

13

 

V.     AUDIT COMMITTEE AND RELATIONSHIP WITH AUDITOR  

        Multilateral Instrument 52-110 of the Canadian Securities Administrators ("MI
52-110") requires the Company, as a venture issuer, to disclose annually in the Information Circular certain information concerning the constitution of its audit
committee (the "Audit Committee") and its relationship with its independent auditor, as set forth in the following. 

        An
Audit Committee charter, the text of which is attached as Schedule "A" to this Information Circular, governs the Company's Audit Committee. 

        The
Company's Audit Committee is comprised of three directors, Peter Winkley, Eric Schneider, David Williams. As defined in MI 52-110, all of the members of the Audit
Committee are "independent". 

 

 

			
	Name

 
	 	Relevant Education and Experience 
	 Peter Winkley
	 	  •       Director and Chair of the Company Audit Committee since
November 2007

	 
	 	  •        Vice-President, Finance and Chief Financial Officer of
Algoma Central Corporation, a public Canadian shipping company.

	 
	 	  •       Former Vice-President Finance and Chief Financial Officer
of Therapure Biopharma Inc., a biopharmaceutical manufacturing company

	 
	 	  •       Former Vice President, Corporate Finance for
MDS Inc. a public life sciences company

	 
	 	  •       Canadian Chartered Accountant and received his B.Com from
the University of Toronto in 1982

	 David Williams
	 	  •       Member of the Board since April 2007

	 
	 	  •       President of his investment company Roxborough Holdings
Limited

	 
	 	  •       Held senior management positions with Beutel
Goodman & Company, one of Canada's largest institutional money managers.

	 
	 	  •       Serves on the boards of Newport Inc., Atlantis
Systems Corp., Western Copper Corp., and Radiant Energy Corporation

	 
	 	  •       Bachelor's degree in Business from Bishop's University, a
Master's degree in Business Administration from Queen's University, and an Honorary Doctorate from Bishop's

	 
	 	  •       Board member of the Bishop's University
Foundation

	 Eric Schneider
	 	  •       Member and Chairman of the Board since
January 2005

	 
	 	  •       Partner in Miller Thomson LLP and its
predecessors

	 
	 	  •       Former board member of 20/20 Financial
Group Inc. (1993-95), Schneider Corporation (1996-99) and Altek Power Corporation (2008)

	 
	 	  •       B.Sc. (Physics) from the University of Waterloo in 1975
and a J.D. from the University of Toronto in 1978

 

         Since
the commencement of the Company's most recently completed financial year, the Board has not failed to adopt a recommendation of the Audit Committee to nominate or compensate an
external auditor. 

        The
Company has not relied on the exemption contained in sections 2.4 or 8 of MI 52-110. Section 2.4 provides an exemption from the requirement
that the Audit Committee must pre-approve all non-audit services to be provided by the auditor, where the total amount of fees related to the non-audit services are
not expected to exceed 5% of the total fees payable to the auditor in the fiscal year in which the non-audit services were 

14

 

provided.
Section 8 permits a company to apply to a securities regulatory authority for an exemption from the requirements of MI 52-110, in whole or in part. 

        The
Audit Committee has not adopted specific policies and procedures for the engagement of non-audit services. The Audit Committee has oversight and must approve all
non-audit services. Currently, the Audit Committee has approved the provision of certain tax advisory services by the Company's auditors. Subject to the requirements of
MI 52-110, the engagement of non-audit services is considered by the Board, and, where applicable, the Audit Committee, on a case by case basis. 

        In
the following table, "audit fees" are fees billed by the Company's external auditor for services provided in auditing the Company's annual financial statements for the subject year.
"Audit-related fees" are fees not included in audit fees that are billed by the auditor for assurance and related services that are reasonably related to the performance of the audit or review of the
Company's financial statements. "Tax fees" are fees billed by the auditor for professional services rendered for tax compliance, tax advice and tax planning. "All other fees" are fees billed by the
auditor for products and services not included in the foregoing categories. 

        The
fees paid by the Company to its auditors in each of the last two fiscal years, by category, are as follows: 

 

 

														
	Financial Year

Ending

 
	 	Audit Fees 	 	Audit Related Fees 	 	Tax Fees 	 	All Other Fees 	 
	 September 30, 2010
	 	 	 $35,177	 	 	 $4,662	 	 	 $4,814	 	 	NIL	 
	 September 30, 2009
	 	 	 $38,000	 	 	 $513	 	 	 $2,754	 	 	 $1,057	 

 

         The
Company is relying on the exemption provided by section 6.1 of MI 52-110 that provides that the Company, as a "venture issuer", is not required to comply
with Part 3 (Composition of the Audit Committee) and Part 5 (Reporting Obligations) of MI 52-110. 

VI.   CORPORATE GOVERNANCE DISCLOSURE  

        National Policy 58-201 — Corporate Governance Guidelines and National
Instrument 58-101 — Disclosure of Corporate Governance Practices set out a series of guidelines for effective corporate
governance. The guidelines address matters such as the composition and independence of corporate boards, the functions to be performed by boards and their committees, and the effectiveness and
education of board members. Each reporting issuer, such as the Company, must disclose on an annual basis and in prescribed form, the corporate governance practices that it has adopted. The following
is the Company's required annual disclosure of its corporate governance practices.  

	1.
	Board of Directors — The Board considers that Messrs. Schneider,
Nadjafi, Williams, Mountain and Winkley are independent according to the definition of "independence" set out in Multilateral Instrument 52-110 as it applies to the Board.
The Board considers that Mr.. Ricks and Dr. Lea are not independent in that they are executive officers of the Company or its subsidiaries. The Board facilitates its exercise of independent
supervision over management primarily by having a majority of the Board members consist of individuals who are independent of the Company.

	2.
	Directorships — Mr. Williams is a director and Audit Committee
member of Western Copper Corp., Resin Systems Inc. Atlantis Systems Corp., and Newport Inc., companies whose shares are listed on the Toronto Stock Exchange. Mr. Williams is also
a director of RoaDor Industries (see "Particulars of Matters to be Acted Upon — Election of Directors — Corporate
Cease Trade Orders, Penalties and Bankruptcies") and Radiant Energy Corporation, companies whose shares are listed on the TSXV. Between April and December 2008, Mr. Schneider was a
director of Altek Power Corporation, a company whose shares are listed on the TSXV.

	3.
	Orientation and Continuing Education — The Board has not adopted a
formal policy on the orientation and continuing education of new and current directors. When a new director is appointed, the Board delegates individual directors the responsibility for providing an
orientation and education program for any new director. This may be delivered through informal meetings between the new directors and the Board and senior management, complemented by presentations on
the main areas of the Company's business. When 

15

 

required
the Board may arrange for topical seminars to be provided to members of the Board or committees of the Board. Such seminars may be provided by one or more members of the Board and management
or by external professionals.  

	4.
	Ethical Business Conduct — The directors are required to abide by all
relevant regulatory rules and regulations. The Board monitors compliance by requiring directors and officers to declare any conflicts of interest or any other situation that could represent a
potential violation of any applicable rules and regulations. When applicable, the Board will receive reports from management regarding any allegations of unethical conduct.

	5.
	Nomination of Directors — The Board has not adopted any formal policy
for the nomination of new directors. The Board relies on each director to identify new candidates for Board nomination based on the needs of the Board.

	6.
	Compensation — The directors of the Company received cash compensation
for their attendance at Board meetings and for acting as chair of certain committees of the Board as well as receiving options to purchase Common Shares. See "Executive
Remuneration — Compensation of Directors". Each of Mr. Ricks and Dr. Lea (both of whom serve as officers of the Company) was each paid an annual
salary of $182,308 and $151,154 respectively. The Board has a compensation committee which is responsible for (i) reviewing the Chief Executive Officer's authorities and accountabilities and
his corporate goals and objectives (which include all performance indicators relevant to the compensation of the Chief Executive Officer); (ii) monitoring the Chief Executive Officer's
performance relative to these goals and objectives; and (iii) formally evaluating his performance at least annually.

	7.
	Other Board Committees — The only standing committees of the Board are
the Audit Committee and the Compensation Committee. From time to time, the Board forms ad hoc committees, as necessary. Given the size of the Company
and the nature of its activities, the Board has not established other standing committees.

	8.
	Assessments — The Board does not have any formal policies to evaluate
the effectiveness of the Board, the Audit Committee and the individual directors. The Board may appoint a special committee of directors to evaluate the Board, its committees and assess the
contribution of its individual directors and to recommend any modifications to the functioning and governance of the Board and its committees. To date, the Board has not appointed any such special
committee of directors to perform such analysis. 

VII. OTHER MATTERS WHICH MAY COME BEFORE THE MEETING  

        Management knows of no other matters to come before the Meeting other those as set forth in this Information Circular. HOWEVER, IF OTHER
MATTERS THAT ARE NOT KNOWN TO MANAGEMENT SHOULD PROPERLY COME BEFORE THE MEETING, THE ACCOMPANYING PROXY WILL BE VOTED ON SUCH MATTERS IN ACCORDANCE WITH THE BEST JUDGMENT OF THE PERSONS VOTING
THE PROXY.

VIII.  GENERAL  

        Except where otherwise indicated, information contained herein is given as of June 8, 2011. 

        The
undersigned hereby certifies that the directors of the Company have approved the contents and the sending of this Information Circular. 

DATED
this 8th day of June, 2011. 

BY
ORDER OF THE BOARD OF DIRECTORS 

/s/
"Claude Ricks" 

Claude
Ricks

President and Chief Executive Officer 

16

 

 
 

  SCHEDULE "A"
  AUDIT COMMITTEE CHARTER
  
    SQI DIAGNOSTICS INC.
  
    (the "Company")
  
    Audit Committee Charter    
    

I      PURPOSE AND AUTHORITY OF THE COMMITTEE  

Appointed
by and reporting to the board of directors (the "Board"), the audit committee (the "Audit
Committee") shall be responsible to: 

	(a)
	assist
the Board in fulfilling its oversight of the Company's financial integrity, specifically by assisting the Board's
oversight of:

	(i)
	the
integrity of the Company's financial statements and other financial reporting;

	(ii)
	the
external auditor's qualifications and independence;

	(iii)
	the
performance of the Company's internal audit functions and internal auditor, if and when one is appointed;

	(iv)
	the
Company's compliance with legal and regulatory requirements; and

	(v)
	any
other matters as defined by the Board;

	(b)
	manage,
on behalf of the shareholders, the relationship between the Company and the external auditors by:

	(i)
	recommending
to the Board the nomination and remuneration of the external auditors;

	(ii)
	overseeing
the work of the external auditors for the purpose of preparing or issuing an auditor's report or performing other audit, review or attest
services for the Company, including the resolution of any disagreements between management and the external auditor regarding financial reporting;

	(iii)
	approving
fees for all audit and audit-related services and pre-approving all non-audit services to be provided to the Company or
its subsidiaries by the Company's external auditor;

	(iv)
	managing
the relationship and facilitating communication between the Company and the external auditors; and

	(v)
	oversee
the preparation of any report that is required by any applicable securities regulatory authority to be included in the annual proxy statement,
annual information form or any other public disclosure document of the Company. 

This
Charter and any subsequent revisions thereto require the approval of the Board. 

The
Audit Committee has the authority to conduct any investigation appropriate to fulfilling its responsibilities, and it has unrestricted access to communicate directly with the internal and external
auditors, management, members of the Board, employees of, or consultants to, the Company and any relevant information. The Audit Committee has the authority to retain, at the Company's expense,
special legal, accounting or other consultants or experts it deems necessary in the performance of its duties and the Audit Committee shall have the authority to set the compensation for any
such advisors. 

II     COMPOSITION OF THE AUDIT COMMITTEE  

The
Audit Committee shall be composed of at least three directors of the Company, appointed by the Board at the annual organizational meeting of the Board or at such other time as may be determined by
the Board and each member shall hold such position until replaced by the Board. The Chairman of the Audit 

17

 

Committee
shall be designated by the full Board, or if the Board does not do so, the members of the Audit Committee, by majority vote, may designate a Chairman. 

Once
appointed, Audit Committee members shall cease to be a member of the Audit Committee only upon: 

	1.
	resignation
from the Audit Committee or the Board,  
	2.
	death,
 
	3.
	disability,
as determined by an independent physician retained by the Board; or  
	4.
	not
being re-appointed pursuant to the appointment process described above. 

Each
member of the Audit Committee shall be an unrelated and independent director as may be defined by the Toronto Stock Exchange and the Ontario Securities Commission from time to time. Each member
shall be neither an officer nor employee of the Company or any of its affiliates. Each member shall be independent of management and must be free from any direct or indirect material relationship with
the Company which could, or, in the view of the Board, could reasonably be perceived to, interfere with the exercise of that member's independent judgement. 

All
members of the Audit Committee shall be financially literate at the time of their election to the Audit Committee, which means that they will have the ability to read and understand a set of
financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be
raised by the Company's financial statements. 

At
least one member of the Audit Committee shall be an "audit committee financial expert" as such term is defined by the Regulations of the Ontario Securities Commission. The Board shall make
determinations as to whether any particular member of the Audit Committee satisfies this requirement. 

A
quorum of any Audit Committee meeting will be a majority of the members of the Audit Committee. The Secretary of the Audit Committee shall be such person as nominated by the Chairman of the Audit
Committee. 

III   MEETINGS OF THE AUDIT COMMITTEE  

The
Audit Committee shall meet at least quarterly or more frequently as it deems necessary to carry out its duties and responsibilities. The external auditors shall receive notice of every meeting of
the Audit Committee and shall be invited to attend and participate in such meetings. The Audit Committee, in its discretion, may also ask members of management or others to attend its meetings
(or portions thereof) and to provide pertinent information as necessary. 

The
Audit Committee Chairman shall approve an agenda in advance of each meeting and shall cause that agenda and related materials to be distributed to members and the external auditor in advance of
said meeting. The Audit Committee shall maintain minutes of its meetings and records relating to those meetings and the Audit Committee's activities and provide copies of such minutes to
the Board. 

As
part of each meeting of the Audit Committee at which the Audit Committee reviews and recommends that the Board approve the quarterly interim financial statements or the annual audited financial
statements, the Audit Committee shall meet separately with the external auditors of the Company. The Audit Committee shall also meet separately with management as it deems appropriate. 

The
Secretary shall circulate the minutes of the meetings to members of the Board, members of the Audit Committee and the head of the external auditor. 

IV    REMUNERATION OF AUDIT COMMITTEE MEMBERS  

No
member of the Audit Committee may earn fees from the Company other than directors' fees (which fees may include cash and/or securities or options or other in-kind consideration
ordinarily available to directors, as well as all of the regular benefits that other directors receive). 

18

 

For
greater certainty, no member of the Audit Committee shall accept any consulting, advisory or other compensatory fee from the Company. 

V     DUTIES AND RESPONSIBILITIES OF THE AUDIT COMMITTEE  

In
carrying out its responsibilities, the Audit Committee shall have the following oversight duties: 

	(a)
	Selection and Evaluation of External Auditors

	(i)
	Make
recommendations to the Board as to the selection of the firm of external public accountants to be nominated to audit the books and accounts of the
Company for each fiscal year.

	(ii)
	Review
and approve the Company's external auditors' annual engagement letter, including the proposed audit plan and fees contained therein, and make
recommendations thereon to the Board.

	(iii)
	Oversee
the work of the external auditors, including the resolution of disagreements between management and the external auditors regarding financial
reporting.

	(iv)
	Receive
from the external auditors there report covering the outcome of their annual audit of the Company.

	(v)
	Make
recommendations to the Board regarding the replacement or termination of the external auditors when circumstances warrant.

	(vi)
	Review
the performance of the Company's external auditors and make recommendations to the Board regarding the replacement or termination of the external
auditors when circumstances warrant.

	(vii)
	Oversee
the qualifications and independence of the Company's external auditors by, among other things:

	(A)
	at
least on an annual basis, evaluating the qualifications, performance and independence of the independent auditor and the senior audit partners having
primary responsibility for the audit.

	(B)
	obtaining
and reviewing a report from the independent auditor at least annually regarding: (i) the independent auditor's internal quality-control
procedures, (ii) any material issues raised by the most recent internal quality-control review, or peer review, of the firm, or raised by any inquiry or investigation by governmental or
professional authorities within the preceding five years respecting one or more independent audits carried out by the firm, (iii) any steps taken to deal with any issues, (iv) all
relationships between the independent auditor and the Company, and (v) the independence of the independent auditor as required by the Regulations.

	(C)
	Approving
the appointment, compensation and work carried out by the external auditors, including the provision of both audit related and
non-audit related services.

	(D)
	Reviewing
policies for the provision of non-audit services by the external auditor and where applicable the framework for
pre-approval of audit and non-audit services.

	(E)
	Requiring
the external auditors to deliver to the Audit Committee, at least annually, a formal written statement delineating all relationships between the
external auditors and the Company and confirming their independence from the Company.

	(F)
	Actively
engaging in a dialogue with the external auditors with respect to any disclosed relationships or services that may impact the objectivity and
independence of the external auditors and recommending that the Board take appropriate action to satisfy itself of the auditors' independence. 

19

 

	(b)
	Financial Statements and Reports

	(i)
	Review
and approve the external auditor's annual Audit plan, including the scope of the external auditor's quarterly reviews and all related fees, and make
recommendations thereon to the Board.

	(ii)
	Review
and discuss with management and the external auditor the Company's quarterly interim financial statements and annual audited financial statements,
including related reports, MD&A, disclosure documents and press releases (paying particular attention to any use of "pro forma" or "adjusted" non-GAAP information), and make
recommendations thereon to the Board prior to public disclosure thereof.

	(iii)
	As
part of the Committee's review of the Company's quarterly interim financial statements, or audited annual financial statements, review and discuss with
management and the external auditors:

	(A)
	The
quality of, and any major issues regarding, the Company's accounting principles and financial statement presentations, including all critical accounting
policies, accounting practices and financial disclosure practices used and any significant changes in the Company's selection or application of accounting principles.

	(B)
	All
significant issues and judgements made in connection with the preparation of the financial statements to determine if and how they should be reported
or disclosed.

	(C)
	The
content and presentation of sales or earnings press releases and any financial information or earnings guidance (if any) provided to analysts and
rating agencies.

	(D)
	Any
outstanding litigation or legal claims or actions which may materially affect the financial position of the Company.

	(c)
	Financial Reporting Process and Internal Controls

	(i)
	At
least annually, in consultation with management and the external auditors the Committee shall:

	(A)
	Consider
the integrity of the Company's financial reporting process and controls, including its computerized information systems.

	(B)
	Review
management's report on its assessment of the significant financial risks and exposures of the Company and the steps taken to monitor, control and
report such risks and exposures.

	(C)
	Review
any significant findings concerning the adequacy of internal controls raised by the external auditors together with management's response(s).

	(D)
	Consider
the effectiveness of the overall process for identifying and controlling the Company's principal financial risks and provide the Audit Committee's
view, including any recommendations, to the Board.

	(E)
	Consider
whether adequate procedures are in place for the review of financial information extracted or derived from the financial statements.

	(F)
	Confirm
through private discussions with the external auditors that no restrictions are being placed on either the scope or the effectiveness of the
external auditor's work.

	(G)
	Consider
the appropriateness of establishing an internal audit function.

	(d)
	Compliance with Laws and Regulations

	(i)
	The
Audit Committee shall:

	(A)
	Review
the effectiveness of the system for monitoring compliance with laws and regulations and the results of management's investigation and
follow-up (including disciplinary action) of any fraudulent acts or non-compliance. 

20

 

	(B)
	Obtain
regular updates from management and the Company's legal counsel regarding compliance matters that may have a material impact on the Company's
financial statements or compliance policies.

	(C)
	Review
the findings of any examinations by regulatory agencies and any correspondence with, or published reports by, regulators or governmental agencies
which raise material issues regarding the Company's financial statements or accounting policies.

	(e)
	Related Party Transactions and Off-Balance Sheet Structure

	(i)
	The
Audit Committee shall:

	(A)
	review
all proposed related-party transactions including those between the Company and its officers or directors and, if deemed appropriate, provide an
opinion regarding any particular transaction to the Board; and

	(B)
	review
all material off-balance sheet structures which the Company is a party to.

	(f)
	Hiring Policies

The
Audit Committee shall review and approve the Company's hiring policies regarding partners, employees and former partners and employees of the present and any former external auditors of
the Company.  

	(g)
	Complaint Procedure

The
Audit Committee shall establish procedures for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls, or auditing matters
and procedures for the confidential, anonymous submission by employees of the Company of concerns regarding questionable accounting or auditing matters. 

VI    EVALUATION OF AUDIT COMMITTEE CHARTER AND COMMITTEE PERFORMANCE  

Annually,
the Audit Committee shall review and assess the adequacy of the Audit Committee charter, report to the Board on the results of such assessment, and recommend any proposed changes to the
Board for approval. 

The
Audit Committee shall also perform an annual evaluation of the performance of the Audit Committee and report to the Board on the results of such evaluation. 

It
is the Board's intention that this charter shall reflect at all times all legislative and regulatory requirements applicable to the Audit Committee. Accordingly, this charter shall be deemed to
have been updated to reflect any amendments to such legislative and regulatory requirements and shall be formally amended at least annually to reflect such amendments. 

While
the Audit Committee has the oversight duties and responsibilities set forth in this charter, the Audit Committee is not responsible for planning or conducting the audit or for determining
whether the Company's financial statements are complete and accurate and are in accordance with generally accepted accounting principles. Management has the responsibility for preparing the financial
statements and implementing internal controls and the external auditors have the responsibility of auditing the financial statements. 

In
discharging its duties, each member of the Audit Committee shall be obliged only to exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable
circumstances. Nothing in this Charter, including designating any member of the Audit Committee as an "audit committee financial expert" is intended, or should be determined to impose on any member of
the Audit Committee a standard of care or diligence that is in any way more onerous or extensive than the standard to which all members of the Board are subject. 

The
essence of the Audit Committee's responsibilities is to monitor and review the activities described in this Charter to gain reasonable assurance (but not to ensure) that such activities are
being conducted properly and effectively by the Company. 

21

QuickLinks

Exhibit 4.2

SCHEDULE "A" AUDIT COMMITTEE CHARTER SQI DIAGNOSTICS INC. (the "Company") Audit Committee Charter

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]